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(HL) have an increased risk of morbidity and mortality associated with secondary effects of therapy, with
a 35-75 fold excess risk of developing breast cancer over the general population. The mechanism for
secondary breast cancer among Hodgkin survivors is not understood. Researchers have postulated that
the familial characteristics of HL could be associated with mutations found within familial cancer
syndromes; however, these mutations have not been identified. This has led to the exploration of inherent
polymorphisms that might impair the patient’s capability to detoxify chemotherapy and/or repair DNA
damage produced by irradiation. Examinations of candidate polymorphisms indicate that single
nucleotide changes may have only a small effect on the development of subsequent cancers. However,
multiple studies support the idea that sensitivity to irradiation and the subsequent development of breast
cancer is mediated through the interaction of multiple genes or gene complexes. The objective of this
case-control study design was to explore the identification of potential candidate genes and
polymorphisms that may be risk factors for the development of secondary breast cancer among women
who are pediatric HL survivors. Global gene expression and genotyping of women with (n=13) and
without (n=36) secondary breast cancer after the treatment of pediatric HL were compared. Differences
were found in global gene expression and genotyping between the cases and controls. Additionally, copy
number variation in association with gene expression found a locus of interest at 15q11.2 in association
with the development of secondary breast cancer.
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ABSTRACT
Identification of genetic risk factors associated with the development of secondary
cancers would facilitate identification of at risk patients and permit modification of
therapy and heightened surveillance that may reduce cancer-related morbidity and
mortality. Women survivors of pediatric Hodgkin lymphoma (HL) have an increased risk
of morbidity and mortality associated with secondary effects of therapy, with a 35-75 fold
excess risk of developing breast cancer over the general population. The mechanism for
secondary breast cancer among Hodgkin survivors is not understood. Researchers have
postulated that the familial characteristics of HL could be associated with mutations
found within familial cancer syndromes; however, these mutations have not been
identified. This has led to the exploration of inherent polymorphisms that might impair
the patient’s capability to detoxify chemotherapy and/or repair DNA damage produced
by irradiation. Examinations of candidate polymorphisms indicate that single nucleotide
changes may have only a small effect on the development of subsequent cancers.
However, multiple studies support the idea that sensitivity to irradiation and the
subsequent development of breast cancer is mediated through the interaction of multiple
genes or gene complexes. The objective of this case-control study design was to explore
the identification of potential candidate genes and polymorphisms that may be risk
factors for the development of secondary breast cancer among women who are pediatric
HL survivors. Global gene expression and genotyping of women with (n=13) and without
(n=36) secondary breast cancer after the treatment of pediatric HL were compared.
Differences were found in global gene expression and genotyping between the cases and
controls. Additionally, copy number variation in association with gene expression found
a locus of interest at 15q11.2 in association with the development of secondary breast
cancer.
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CHAPTER 1. INTRODUCTION
Problem
Overall survival of pediatric Hodgkin lymphoma (HL) is 90%; however, due to
late treatment complications including subsequent malignancy, survival decreases with
time [1, 2] . Women survivors of pediatric HL have an increased morbidity and mortality
associated with secondary effects of therapy, most specifically those associated with
radiation [3-6]. It is estimated that the relative risk of breast cancer among HL women
survivors treated prior to 30 years of age is 6 to 17-fold [7-9], with the largest relative
risk ranging from 60-fold to 112-fold for those treated at 16 years of age or younger [7,
8, 10]. Furthermore, these women have reached a 12.9% cumulative incidence of breast
cancer by 40 years of age [3], and at 50 years of age many HL survivors treated with
chest radiation have exceeded the lifetime risk of developing breast cancer as compared
to the general population which is a 13.4 % lifetime cumulative incidence, one in eight
women [11, 12]. The relative risk for secondary breast cancer is highest at 15 to 20 years
after initial HL radiation [3, 5, 7], while an increased cumulative absolute risk of breast
cancer reflects background breast cancer associated with increasing age [11]. In
comparison to other high risk breast cancer groups such as BRCA1 and BRCA2 carriers,
women treated for HL at a young age with radiation therapy and without alkylating
agents may only have a modestly smaller risk than the high risk carriers of the BRCA
mutation [11]. Therefore, women HL survivors are at a significantly high risk for the
development of breast cancer and remain so throughout their lifetime.
The mechanism for early age on-set breast cancer among Hodgkin survivors is not
understood; however, specific characteristics have been identified as being risk factors
and include: age at the time of HL diagnosis[3, 5-7, 11, 13, 14], radiation exposure[5, 7,
11, 13-16], endocrine function[13, 14], and familial cancer history [3]. Studies show that
other risk factors such as administration of combined modality therapy [7], alkylating
agents [3, 13, 14, 17], pelvic radiation [13], pregnancy, and use of hormonal therapy have
conflicting associations to secondary breast cancer among HL survivors.
In attempting to better understand the mechanism of secondary breast cancer,
researchers have postulated that the familial characteristics of HL and high incidence of
secondary breast cancer may result from mutations similar to those identified in inherited
breast cancer syndromes. To date, inherited mutations such as TP53, BRCA1, BRCA2,
and heterozygous ATM mutations have not been identified among HL survivors with
secondary breast cancer [3, 18, 19]. While many of the associated risk factors of
secondary breast cancer are well documented, there have been no association studies that
have linked an identified genetic risk factor marker.
Failure to identify commonly inherited mutations or markers has led to the
exploration of inherent polymorphisms that might impair the patient’s capability in
detoxification of chemotherapy and/or repair of deoxyribonucleic acid (DNA) damage
produced by radiation [20, 21]. Examination of these candidate polymorphisms has
1

found that single nucleotide changes may have only a small effect on the development of
subsequent cancers and the strongest effect on secondary cancer development is perhaps
a gene-gene interaction. This is evident in studies that support the idea that sensitivity to
radiation and the subsequent development of breast cancer is mediated through the
interaction of multiple genes or gene complexes [18, 19, 21].
Thus far, the association of candidate genes and polymorphisms and the
development of secondary breast cancer have not been found. To my knowledge, there
has not been a whole genome association study examining the global gene expression and
single nucleotide polymorphisms associated with HL and secondary breast cancer. To
explore the genetic contribution to this complex disease, the purpose of this study was to
identify gene expression patterns and candidate polymorphisms that may be risk factors
for the development of secondary breast cancer. Study methods focused on identifying
differential gene expressions between two groups of women who are pediatric HL
survivors; those who developed secondary breast cancer (case) and those who have not
(control) developed secondary breast cancer within 20 years after HL diagnosis.
Individual global gene expression was characterized and associated with their expressed
polymorphism (mutation). The gene expression was measured by microarray analysis and
an association study correlated the genotypes at 500,000 single nucleotide polymorphism
(SNP) loci with the gene expression levels. The study also examined gene and
polymorphism expression differences between the case and controls and identified global
gene expression and the associated genotype copy number variation among the cases and
controls. Association data will provide candidate genes, polymorphisms and a region of
copy number variation for consideration in the etiology of secondary breast cancer after
HL therapy. Furthermore, identification of genes, polymorphism, and copy number
variations associated with the development of secondary cancers would facilitate
identification of at risk patients and permit modification of therapy and heightened
surveillance that may reduce cancer-related morbidity and mortality.
Primary Aims
The primary aims were to:
1. Assess whether global gene expression profiles differ between two groups of
radiated pediatric female HL survivors with (cases) and without (controls) the
development of secondary breast cancer.
1.1.
1.2.
1.3.

Identify the gene expression profile for cases
Identify the gene expression profile for controls
Identify the gene expression profile similarities and differences between
cases and controls

2. Assess whether genotype profiles differ between two groups of radiated pediatric
female HL survivors with (cases) and without (controls) the development of
secondary breast cancer.
2

2.1.
2.2.
2.3.

Identify the genotype profile for cases
Identify the genotype profile for controls
Identify the genotype profile similarities and differences between cases
and controls

3. Identify potential candidate genes through identifying copy number variations that
associate with the risk of secondary breast cancer.
The secondary aim was to explore the associations among lifestyle characteristics
(hormone use, pregnancy, lactation), family history and the occurrence of breast cancer.
Significance
According to the American Cancer Society, over 7,000 new cases of HL were
diagnosed in 2005 with 10-15% of these cases occurring in children 16 years and younger
[22]. With the combination of chemotherapy and radiation, the 5-year survival for those
with low stage disease is 85-95% and 70-90% survival for those with advanced disease
[12]. The intensity of therapy is stage-related.
With improved therapy it is now estimated that among the general population 1 of
every 300 young adults < 45 years of age is a survivor of childhood cancer [22].
Furthermore, cancer survivors of all ages comprise 3.5% of the United States population.
Although these individuals have survived cancer, they are at greater risk for subsequent
cancers. Approximately 16% of the annual cancer incidence occurs as a second cancer in
a cancer survivor [23]. One of the most devastating event for any cancer survivor is the
occurrence of a second cancer, but particularly devastating is the second cancer for a
young adult who is starting a career and family. As cancer survival rates increase so will
the number of survivors who will experience a secondary cancer.
Recently, there has been an increased interest and concern regarding the health
status and late effects associated with childhood cancer care, most specifically the late
effect of secondary cancers. Studies have found one of the highest occurrences of second
cancers is among women who are HL survivors [3, 4, 6, 7]; therefore, it is of importance
that factors contributing to secondary cancers in this group be identified.
While environmental risk factors such as radiation have been identified, inherent
risk factors are just beginning to be studied. Identification of secondary breast cancer
inherent risk factors could provide an at risk patient profile at the time of initial diagnosis.
This profile would be important when considering therapeutic agents that may be added
or deleted in the initial treatment of HL resulting in a reduction of late effects. Lastly, one
could foresee the high risk profile individual being counseled, screened, and offered
preventive therapies such as those of known breast cancer risk associated with BRCA1
and BRCA2 gene mutation.
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The primary focus of this study was to begin the development of an inherent
genetic risk patient profile. Thus far the candidate gene approach has not found evidence
of known inherited mutations among those with secondary breast cancer [3, 18, 19].
Therefore, this study explored the comparison between an individual’s genotype in
consideration of treatment variables that may contribute to the increased incidence of
secondary breast cancer among HL survivors compared to non-secondary breast cancer
HL survivors. This study took advantage of rapidly evolving biotechnology in gene
profiling and genotyping using microarray technology. The global gene expression and
genotypes of HL survivors with breast cancer was explored to identify potential candidate
polymorphisms associated with genotype allele frequency and the possible contribution
of the genotype to the development of secondary breast cancer. Identification of potential
polymorphisms will be valuable in the development of future research projects in
replication and validation within larger samples of HL survivors with secondary breast
cancer.
Gene profiling and genotyping technology is quickly advancing and showing
significant progress in the identification of prognostic indicators for complex disorders. A
number of studies have identified prognostic and predictive ‘gene’ signatures as
prognostic indicators in the treatment of breast cancer [24]. Most of the early work with
microarray analysis and primary breast cancer has been done with tumor samples taken at
the time of breast surgery. These analyses have enabled researchers to analyze breast
tissue and obtain a better understanding of the molecular characteristics and clinical
behavior of breast cancer. This has been most helpful in the analysis of gene
amplification and coamplification in prognosis and treatment of breast cancer [25]. While
tissue study is beneficial in determining prognosis and treatment response, molecular
expression from a tumor sample presents difficulty in determining the causality of the
tumor due to both primary and secondary chromosomal changes. Primary changes are
present in all tumor cells, while secondary changes are associated with revascularization
or the development of metastatic disease [26]. Examination of breast tissue will give
expression at the site of the disease and reflect the characteristics of the individual tumor,
but will not give a global picture of the gene interaction that may have predisposed an
individual to cancer. With the hypothesis that the second cancer is the result of an
inherent gene-gene/environment interaction, breast tissue would not reflect inherent or
germline expression. Therefore, this study will explore the use of peripheral blood as a
potential predictor of germline genetic risk for the occurrence of secondary breast cancer.
Lastly this study is significant for its interdisciplinary approach. Nurses can play a
pivotal role in the era of genomic research through their skill of design, interdisciplinary
interaction in completing the methodology and analysis, and the nurses’ skill of research
dissemination with translation into practice. The nurse-patient rapport provides an
excellent navigational environment for the nurse to describe genomic screening, provide
a clear translation of the findings, as well as the implications for treatment decision
making and follow-up. It is also imperative that the patient have an update family history
with particular emphasis on family history of cancer and most specifically breast cancer.

4

Conceptual Model
This study evaluated the similarities and differences in genotype allele frequency
and the associated global gene expression between individuals treated for pediatric HL
with and without the development of secondary breast cancer. The conceptual model (see
Figure 1.1) depicts an individual with diagnosed HL involving the mediastinum. The
standard HL therapy is combination chemotherapy and radiation at the site of disease.
With the presence of mediastinal HL, most individuals receive radiation therapy to the
mediastinum disease. At the initiation of treatment, each individual has inherent
characteristics including familial inherited characteristics and individual genetic
differences within their individual nucleotide sequence known as polymorphisms. In
addition, each individual has specific treatment related risk factors. These risk factors
include: age at HL diagnosis[3, 5-7, 11, 13, 14], dose of mediastinal radiation [5, 7, 11,
13-16], administration of alkylating agents [3, 13, 14, 17] and pelvic radiation [13].
During the therapeutic administration of mediastinal radiation there is an interaction
between the inherent and treatment characteristics (gene-environment interaction). Both
the case and control have ablation of Hodgkin tumor, but the case will have retention
and/or disrepair of mutated deoxyribonucleic acid (DNA) within the non-diseased breast
tissue. The control group will have repair and/or apoptosis of mutated DNA in the nondisease breast tissue. Overtime, both groups will undergo additional genetic insults from
exposures within the individuals’ environment. For each case, penetrance of secondary
breast cancer is dependent upon persistent and additional somatic mutations [27]. As a
result of the retained mutated DNA and successive mutations, the secondary cancer will
occur approximately 15-20 years after the initial DNA mutation initiated by radiation [3,
7, 8].
Determining the genotype differences among the cases and controls was
accomplished through the technology of DNA and expression microarray. The human
genome is made of 3 billion base pairs with single nucleotide polymorphisms (SNPs)
noted between individuals at every 1000 base pairs. Furthermore, it is these
polymorphisms that give “biochemical individuality” among the human species [28].
With the interaction of one’s biochemical pathways (gene-gene interaction), regardless of
one’s state of health, there is a genetic predetermined chemical individuality that
responds to environmental and pharmacological influences (gene-environment) [28].
Microarray technology has predominantly been utilized in the analysis of
expressed genes within and between biologically matched subjects; however, with human
genome mapping they can now be utilized for study of genetic variations among
individuals and referred to as SNP analysis. SNP analysis is useful in linkage analysis for
identification of disease markers, loss of heterozygosity (LOH), uniparental disomy, for
analysis of tumor suppressor genes, and association studies to link SNPs to overly or
underly expressed genes [29]. Therefore, this proposal utilized whole genome analysis of
gene expression and genotyping at polymorphic sites between cases and controls. The
gene expression was analyzed from the extracted RNA, while genotyping (SNP) data
were analyzed from the extracted DNA.
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Inherent Risk
Factors
-Family History
-Genetic
Polymorphism

Mediastinal Hodgkin
lymphoma

Treatment
Related Risk
Factors
-Age at Radiation
-Dose of Radiation
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-Pelvic Radiation

Radiation Therapy to Mediastinum
Cellular DNA Disruption of tumor
and non-diseased tissue

Ablation of tumor
Repair of mutated
DNA in nondiseased tissue
Apoptosis

Ablation of tumor
Retention of
mutated DNA in
non-diseased
tissue
Additional Genetic Insults
Over time

Non
Development of
Early on-set
Breast Cancer
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Development of
Early on-set
Breast Cancer
(Case)

Expression Data
- Global gene expression profile
- Genotype profile
- Copy Number Variation

Identification of potential candidate genes,
polymorphisms, and regions of copy number
variation

Figure 1.1 Conceptual Model Describing the Events Following Mediastinal Radiation in
Case and Control, with the Utilization of Gene and Genotype Expression as a Predictor.
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The goal of the study was to acquire an enhanced understanding of the biological
pathway leading to the development of secondary breast cancer, and identification of
potential biomarkers that may identify women at risk. It is hypothesized that genetic
differences between the case and control are responsible for a differential response to
initial DNA damage. Accumulation of DNA mutations at different rates would lead to
early onset of secondary breast cancer. The gene expression and genotype profiles were
compared between cases and controls as well as the copy number variation. This analysis
identified potential candidate genes and a site of deletion for consideration in the etiology
of secondary breast cancer. Once women are identified as being at risk, treatment may be
modified for prevention of therapy related morbidity/mortality thereby improving quality
of life.
Definition of Terms
•

•

•

•

•
•
•

Hodgkin lymphoma (HL): Participants within this study, both cases and
controls, were diagnosed with HL prior to 25 years of age. The diagnosis of HL
was based upon pathological examination of lymph node tissue and documented
in the medical record.
Case (Secondary Breast Cancer): Participants classified as cases were surviving
women who were treated for pediatric HL with mediastinal radiation and
subsequently developed breast cancer prior to 50 years of age. The diagnosis of
secondary breast cancer is based on pathology examination and documented in
the medical record.
Control (Non-Secondary Breast Cancer): Participants classified as controls
were surviving women who were treated for pediatric HL with medialstinal
radiation and have not developed any subsequent cancer. These women will have
a negative mammogram within one year of the study and a negative history for
proliferative breast disease. This data was obtained through participant reporting.
Copy Number Variation: Copy number variation gives the number of DNA
segments within the genome. It was thought that genes were present in two copies
but is now known that there is variability and DNA segments may be lost or
gained. This gives an insight into the variability among individuals and may
contribute to disease.
Genotype: Genotype is an individuals’ set of alleles that make up ones genetic
constitution, either collectively or at a single locus. This study explored
differences in genotypes using single nucleotide polymorphisms.
Phenotype: Phenotype is the observable characteristics of an individual, resulting
from the interaction of the genotype and environment.
Single Nucleotide Polymorphism (SNP): Single nucleotide polymorphisms are
found throughout an individual’s genotype and may affect phenotype. A SNP is a
DNA marker and designates differences in the DNA sequence of homologous
chromosomes. For the DNA differences to be termed a SNP, they must be present
in more than 1% of the population [30]. The genotype expression, the presence of
single nucleotide polymorphisms (SNP), was measured with the Affymetric
GeneChip® Human Mapping 500K Set.
7

•

•

•
•

Gene Expression: Gene expression is the process of transcription of DNA into
messenger ribonucleic acid (mRNA) and translation of the mRNA into protein.
This study will assess an individuals’ gene expression and the association of this
expression to the genotype. The differences in global gene expression between
cases and controls will be measured with the Affymetrix GeneChip® Human
Genome U133 Plus 2.0 Array.
Microarray: Microarray analysis allows genomic measurement of an individual’s
gene expression under a variety of genetic and environmental conditions. The
mRNA is reverse transcribed to complimentary DNA (cDNA) and labeled with
fluorescent dyes and hybridized to the microarray glass slide. The glass slide has
oligonucleotides arranged in columns and rows which are constructed for a
specific gene. Lasers are then used to generate an image from the sample. The
data are expressed in a matrix with columns indicating samples and rows
indicating genes [31]. The Affymetrix GeneChip® Human Genome U133 Plus
2.0 Array will analyze gene expression. Microarray technology also has the
application for detection of polymorphisms within an individuals’ genome. The
DNA is labeled with fluorescent dyes and hybridized to the microarray. The array
has oligonucleotides that are associated with 500,000 known SNPs within the
genome. This study will use the Affymetric GeneChip® Human Mapping 500K
Set for SNP analysis.
Gene-Environment Interaction: A gene to environment interaction occurs when
the environmental effects on phenotype differ according to the individual
genotype.
Gene-Gene Interaction: The regulated expression of genes is dependent upon
complex interrelationships among genes within the genome. Changes within this
interrelationship among genes can significantly affect biological pathways [28].
Assumptions

1. Women diagnosed with pediatric HL are a vulnerable host for recurrent
malignancies.
2. HL survivors with and without breast cancer have a genetic predisposition that
responds differently to radiation exposure.
3. The gene expression profile between the cases and controls may not differ due to
cumulative absolute risk of breast cancer among controls due to background
breast cancer associated with increasing age.
4. The identified gene pathways will direct future research in the study of candidate
genes that had not been previously considered.
5. Ultimately, identification of polymorphisms and copy number variation could be
integral in the development of a predictive model for those at risk of secondary
breast cancer.
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Potential Limitations
1. Much research has focused on the genetic study of primary breast cancer;
however, these data may not be generalizable to other breast cancer patients. Most
breast cancer research has focused on the genetic characteristics of the tumor,
while this study will focus on the inherent individual characteristics that
predispose one to the development of breast cancer.
2. Secondary breast cancer is most often diagnosed 15-20 years after the initial HL
diagnosis; however, this will vary among individuals [3, 7, 8]. All controls will
have undergone the passage of 15 to 20 years since diagnosis and will be matched
with the cases on time since diagnosis; however, a control could become a case
during the course of the study.
3. Blood samples for gene expression were collected at outlying physician’s offices
and mailed to a designated lab for RNA extraction. If collection, storage, and
mailing were not completed as instructed, there may have been degradation of the
RNA in transport. If RNA degradation occurs, there may be loss of transcripts and
gene expression. However, each sample will undergo a quality control analysis
before processing and another RNA sample will be submitted if needed.
4. Methods are available to compute power and sample size for most gene
expression microarray studies [32]. However, power and sample size calculations
were not used to design this study due to the limited number of cases. Thus, the
statistical power to find meaningful associations may be quite low.

9

CHAPTER 2. REVIEW OF LITERATURE
Hodgkin Lymphoma
In 1832, Thomas Hodgkin published a paper entitled, “On Some Morbid
Appearances of the Absorbent Glands and Spleen” describing lymph node and spleen
enlargement in what came to be known as Hodgkin lymphoma [33]. At the turn of the
century, diagnosis was dependent upon the microscopic morphology of tissue and
Hodgkin tumors were recognized to have abnormally giant cells. These giant cells were
first described by Sternberg [34] and Reed [35] who were credited with describing HL
histopathology, hence the naming of the Reed Sternberg cells found within HL tumor.
Until recently the malignant cell of HL origin has remained unknown. New
technologies such as polymerase chain reaction (PCR) and micro laser dissection have
assisted in determining clonal immunoglobulin rearrangements and the origin of
malignancy as B-lymphoid cells [36, 37]. The World Health Organization (WHO) has
now renamed Hodgkin disease to Hodgkin lymphoma reflecting an understanding of its
B-cell origin [38].
It is estimated that only a small portion (0.1% to 10%) of the HL tumor is
malignant [38]. HL tumors are primarily comprised of inflammatory cells including
lymphocytes, neutrophils, eosinophils, histiocytes, plasma cells and fibrosis. The
malignant cells found in HL are the Reed-Sternberg cell and mononuclear/multinucleated
variants. The Reed-Sternberg cell is a large binuclei or binuclear lobe cell and within
each of the nuclear lobes are large eosinophilic nucleoli larger than neighboring
lymphocytes. HL cells may also be highly pleomorphic creating difficulty with diagnosis
and a differential to include high-grade sarcomas and diffuse large cell lymphomas with
anaplastic features [39].
Histological Subsets
The WHO classification recognizes two major subsets of HL, classical Hodgkin
and nodular lymphocyte predominant Hodgkin [38]. This classification is based on the
tumor morphology and immunophenotype. Classical Hodgkin is categorized into four
subsets and includes: nodular sclerosis subtype, mixed cellularity subtype, lymphocyterich subtype, and lymphocyte depleted subtype. All subtypes of HL are equally
responsive to treatment [39].
Hodgkin Staging
In 1971, the Ann Arbor staging for HL was developed, this staging was based on
the knowledge that HL progressed along lymph node chains [40]. Substage classification
is also determined at diagnosis according to clinical symptoms at presentation and
includes A, B, and E substage. At presentation, the history includes notation of
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constitutional symptoms which include fever >38º c for 3 consecutive days, drenching
night sweats, and weight loss of  10% of body weight over the previous 6 months. Upon
presentation, a patient without these symptoms is classified as an A substage; however, if
these symptoms are present they are classified as B substage. Patients with E substage
have extralymphatic extension of disease directly from nodal disease. The Ann Arbor
Staging Classification of HL is described in Table 2.1.
Hodgkin Lymphoma Therapy
Radiotherapy was the first effective treatment for HL, providing high doses of
radiation to large fields. Then in 1964, a four-drug regime (MOPP) was introduced as the
first effective systemic therapy for HL. The MOPP regime includes mechlorethamine
(nitrogen mustard), Oncovin (vincristine), procarbazine, and prednisone. This regimen
resulted in a prolonged disease free survival in more than 50% of adult and pediatric
patients. However, the treatment was found to have significant late effects including
acute myeloid leukemia (AML) and infertility. To reduce the risk of AML, another
alkylating agent, cyclophosphamide (COPP) was substituted for mechlorethamine. In
1970, the ABVD (Adriamycin (Doxorubicin), bleomycin, vinblastine, and dacarbazine)
regimen was introduced and did not have the associated late effects of AML and
infertility. While this regimen has led to superior outcomes in adults, the regimen has
been of concern in pediatrics due to the risk of cardiopulmonary toxicity. Through the
1980’s, this combined approach of multi-agent chemotherapy and extended volume
radiation delivered at standard dose of 35-44 Gray (Gy) was the treatment of choice [39].
Overtime, significant late effects were noted in HL survivors as a result of the radiation.
These late effects resulted in investigating the effectiveness of combined multi-agent
chemotherapy with low dose involved-field radiation delivered at the dose of 15-25.5 Gy
[41, 42].
In the 1990’s, investigators found that multi-agent chemotherapy with low dose
radiation did not compromise disease-free survival. Children and adolescents are now
treated for HL with risk-adapted, combined-modality therapy using multiagent
chemotherapy and low-dose involved field radiation [39]. For children with low-stage,
nonbulky disease, chemotherapy alone is being investigated [39]. The objective of risk
adapted therapy is to provide disease-free survival with minimization of treatment-related
sequelae including musculoskeletal deformity, cardiopulmonary, and second malignancy.
Hodgkin Lymphoma Therapy of Cases and Controls
The cases and controls for this study were treated at St. Jude Children’s Research
Hospital (SJCRH) between 1970 and 1991, according to institutional protocol. These
protocols included: HOD 68, HOD 72, HOD 80, and HOD 90. During the years 19691972, HL patients were treated according to the HOD 68 protocol. This protocol
delivered combined chemotherapy agents; cyclophosphamide, vincristine +/procarbazine and prednisone plus radiation therapy at doses ranging from 35-44 Gy
11

Table 2.1 Ann Arbor Staging Classification.
Stage

Definition

I (A/B)

Involvement of a single lymph node region (I) or of a single
extralymphatic organ or site (IE)

II (A/B)

III (A/B)

IV (A/B)

Involvement of two or more lymph node regions on the same side of
the diaphragm (II) or localized involvement of an extralymphatic
organ or site and one or more lymph node regions on the same side of
the diaphragm (IIE)
Involvement of lymph node regions on both sides of the diaphragm
(III), which may be accompanied by involvement of the spleen (IIIS) or
by localized involvement of an extralymphatic organ or site (IIIE) or
both (IIISE)
Diffuse or disseminated involvement of one or more extralymphatic
organs or tissues with or without associated lymph node involvement
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delivered to extended volume fields. The HOD 72 protocol was opened in 1972-1980 and
compared standard dose radiation therapy at doses 35-44 Gy alone to radiation therapy at
doses 35-44 Gy plus chemotherapy agents cyclophosphamide, vincristine, procarbazine,
and prednisone (COPP). The HOD 80 protocol was opened in 1980-1984 and combined
chemotherapy COPP with lower dose radiation at 20 Gy extended-volume. In 1984-1990,
the HOD 80A protocol was open and continued utilization of lower dose radiation at 20
Gy; however, the radiation was delivered to only the field of disease involvement.
Alternating cycles of chemotherapy were administered and included COP(P) and ABVD.
Prednisone was only administered to patients with “B” symptoms. HOD 90 was
opened in 1990 and was the first protocol to classify patients according to risk. The low
risk arm therapy consisted of 4 cycles of vinblastine, adriamycin, methotrexate, and
prednisone (VAMP) and low dose involved field radiation delivered between 15-25.5 Gy.
The radiation dose was determined according to disease response after two cycles of
VAMP. High risk patients received 6 cycles of chemotherapy which included vincristine,
etoposide, prednisone, and adriamycin (VEPA) followed by 25.5Gy radiation therapy.
Radiation therapy was not initiated until after the second cycle of chemotherapy except
for patients with extensive disease who began radiation after the completion of all
chemotherapy. Patients that required more than one treatment field of radiation received
the later courses of radiation after the fourth or sixth course of chemotherapy.
Secondary Malignancy
Children and adolescents treated for HL have a higher incidence of long-term late
effects secondary to treatment when compared to other childhood cancer survivors [1, 11,
41]. One of the devastating late effect for any cancer survivor is the occurrence of a
second cancer. A large HL cohort followed for 27.8 years found the estimated cumulative
incidence of any second cancer was 10.6% at 20 years and increasing to 26.3% at 30
years. The estimated cumulative incidence of solid tumors was 7.3% at 10 years and
increasing to 23.5% at 30 years, with breast cancer being the most common solid tumor.
The most surprising finding was the incidence of a third cancer with the estimated
cumulative incidence of 21% at 10 years after the second [10].
Breast cancer is the most common cancer among women and is the second
leading cause of death from cancer [1]. Women treated for HL with mediastinal radiation
at 30 years of age or younger have the highest incidence of breast cancer, outside familial
syndromes [11]. The risk is greatest at 15 to 20 years after initial HL diagnosis, which is
more than 20 years before the median age (61years) of breast cancer among the general
population [3, 7, 20]. The mechanism for secondary breast cancer following mediastinal
radiation is not well established, but specific risk factors have been identified. Specific
demographic and treatment characteristics identified as risk factors contributing to
secondary breast cancer include: dose of mediastinal radiation, age at the time of HL
diagnosis and therapy, endocrine function, and familial cancer history including inherent
genetic variability [3-6, 8, 12, 13].
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Researchers have developed predictive models of cumulative risk of breast cancer
among women treated for HL [11] based on treatment, age at therapy and length of
follow-up as well as family history. It could be argued that pediatric HL patients treated
on identical treatment regimens are matched on the variables of treatment, age, and
follow-up; therefore, all are seen as high risk for secondary breast cancer. Therefore, the
genetic variability at the time of therapy may play the greatest role in determining those
of increased sensitivity to the prescribed therapy, most specifically radiation. A recent
study found an increased relative risk of breast cancer after HL with a positive first
degree family history of cancer [43]. While the family history is a significant predictor of
future health status, family history in the pediatric patient should also consider the health
status of second degree relatives. Many of the first degree relatives of pediatric HL
patients may not have developed a cancer due to the background of time, while predictors
may be with the secondary degree family members. For the pediatric HL survivor one
should consider all the associated risk factors; radiation, chemotherapy regimens, age at
therapy, and family history; however, there appears to be no straightforward predictor for
the development of secondary breast cancer [44].
Demographic and Treatment Characteristics of the Primary Cancer
Radiation
The risk factor that is most strongly associated with the development of secondary
breast cancer is mediastinal radiation including the radiation dose received as part of the
treatment for HL. The radiation dose of  40 Gy has been associated with the highest risk
of secondary cancer with a 23.3 fold increase in comparison to 20-39 Gy which is
associated with a 5.9 fold increase [15]. While the lower dose of radiation is thought to
reduce risk of secondary cancer, women who received radiation therapy alone at doses of
4 Gy to the breast continued to have a 3.2 fold increase in development of breast cancer
[13]. Another study found that the risk of secondary breast cancer was increased in HL
patients compared to the general population regardless of the radiation dose [5]. Although
current treatment protocols use combined modality therapy, the risk of lower dose
radiation < 20 Gy has not been established. It is believed that the reduction in volume of
exposed breast tissue and radiation dose reduction to 20-30 Gy will change the long-term
risk profile of patients cured of HL [45]. While the association has been made with
radiation and the occurrence of a secondary breast cancer, there is clearly no radiation
dose that is without the risk of breast cancer. All pediatric HL survivors treated with chest
radiation appear to be at an increased risk regardless of the radiation dose.
Age at HL Diagnosis
Along with radiation, age at the time of HL diagnosis has been implicated as a
risk factor for secondary breast cancer. As stated earlier, the greatest risk of secondary
breast cancer has been found in women treated for HL prior to the age of 30 years [7, 13].
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Women radiated prior to 30 years of age appear to have an excess risk 15-20 years after
therapy and beyond 20 years, with a 2.3-3.7% excess risk per person per year [8].
Young age at the time of radiation and the occurrence of breast cancer parallels
the well established concept of increased sensitivity of young breast tissue to ionizing
radiation [11]. An earlier age of risk has been proposed by Travis et al. [13] who
determined the relative risk (RR = ratio observed/expected) of radiation associated breast
cancer for subgroups defined by age and found the risk to be greatest in women who
received radiation therapy at the time of puberty, 13-17 years. Another study explored the
risk factor of age using the multiple Poisson regression of standard incidence ratios. The
regression model analysis found the risk of secondary breast cancer to be greatest in girls
treated for HD at 5-9 years of age [6]. To further explore the correlation of age at HL
diagnosis and secondary breast cancer, another study used two statistical approaches, the
Cox regression and Poisson regression of standard incidence ratio. Each method had
similar results and the study concluded that there is little statistical evidence for an
association between age at diagnosis of HL and the development of secondary breast
cancer [46]. As noted, the studies that have examined the association of secondary breast
cancer and age at HL treatment have found varying ages of association. It is known that
women undergo an increase of breast tissue proliferation during the early menarche years
and first pregnancy [47]. Therefore, an age of radiation therapy prior to 30 years is
perhaps more inclusive of those at risk of secondary breast cancer and would include the
ages of breast vulnerability. While the relative risk of breast cancer is highest 15-20
years after radiation therapy, this relative risk will decrease with time. However, due to
the background risk of breast cancer with increasing age, HL survivors have a decreased
relative risk and an increased absolute risk and cumulative incidence of breast cancer
with age [7].
Endocrine Influences
Ovalatory function and most specifically the greater number of lifetime ovulatory
cycles has been well established as a risk factor associated with breast cancer. This
lifetime exposure to sex hormones is determined by age at menarche, age at first full
pregnancy, the number of pregnancies, and age at menopause. Early menarche is less
than 12 years of age for initiation of menses and is thought to increase breast cancer risk
secondary to prolonged breast exposure to estradiol during adolescence [48]. In relation,
the delay of menopause maximized the number of ovalatory cycles and may therefore
increase breast cancer risk. Many women with significant risk factors for breast cancer
are advised to have ovariectomy prior to 45 years to induce menopause and thus
decreasing breast cancer risk by 40% [49].
After radiation, the risk of secondary breast cancer increases if the women has a
larger number of premenopausal years due to prolonged ovulation and hormonal
influences [14]. Women treated for HL have been found to experience early menopause
secondary to ovarian irradiation and alkylating chemotherapy which results in ovarian
dysfunction, reduced hormonal influence, and a theorized reduction in breast cancer risk
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[11, 13, 14]. Reaching menopause, as early as 31 years of age has been associated with
the strongest reduction in breast cancer and remains beneficial if achieved by 36 years in
comparison to those remaining premenopausal or entering menopause after 45 years of
age [14]. Additionally, the relative risk is reduced if there are less than 15 years of
ovulation after HL therapy [14]. After HL therapy, ovarian failure may occur at a
radiation dose of 5 Gy or more to the ovaries, and ovarian failure is greatest when the HL
treatment includes both pelvic radiation and alkylating agents [13, 14]. According to
Travis et al. [11], women treated with radiation and alklyating agents had a 1.4 fold
increased risk of secondary breast cancer in comparison to a 3.2 fold increase in women
treated with radiation alone; therefore, the addition of alkylating agents further decreased
the ovarian function and decreased the breast cancer risk. Other data suggest that young
women treated with mediastinal radiation without alkylating agents have increased risk,
comparable or slightly smaller than those with BRCA mutations who have a 65-80% risk
[11]. Another study found a protective effect of pelvic radiation, but did not find a
protective effect of alkylating agents even at higher doses [3]. Although the use of
alkylating agents has been documented as being protective, the timing of the alkylating
exposure may effect the chemotherapies induction of premature menopause [50].
Furthermore, Travis et al found the trend of protection was not statistically significant in
HL patients when treated at 21 years of age or younger [13]. While several studies have
cited the administration of alkylating agents and pelvic radiation to be breast cancer
protective, pelvic radiation may be the most protective among pediatric HL patients. For
the patient less than 21 years of age the administration of alkylating agents without pelvic
radiation may offer little benefit of early menopause. To determine the effect of
chemotherapy and pelvic radiation, dosing of alkylating agents and chemotherapy was
determined for each case and control within the study.
The use of exogenous hormones is strongly linked to an increased risk of breast
cancer among postmenopausal women within the general population [51]. The link of
exogenous hormones and breast cancer has also been made in women using oral
contraceptives. A large meta analysis found that risk was strongest while taking oral
contraceptive, with a persistent decreasing risk up to 10 years after hormone cessation.
Additionally, this analysis found initiation of oral contraceptive prior to 20 years of age
increases risk as opposed to initiation at an older age [52]. Studies have examined the
association of hormone use after HL therapy and have been unable to clarify the risk of
early on-set breast cancer, hormone therapy and HL [14, 53]. The question remains if use
of hormone therapy diminishes the beneficial effect of premature menopause and should
all HL survivors discontinue hormone therapy by 31 years of age, when menopause is
most beneficial.
In addition to chemotherapy and radiation, the endocrine function of ovulation is
decreased with pregnancy and is associated with a decreased breast cancer risk,
especially with early age at first pregnancy. A study of Japanese bomb survivors found
that the dose of radiation and nulliparity act multiplicatively in causing breast cancer with
parous women giving birth at a younger age demonstrating lowest risk [54]. Although
pregnancy decreases the number of ovalatory cycles and is protective, the exposure of
pregnancy hormones on breast tissue results in an increased risk for primary and
16

secondary breast cancer 3 to 7 years after childbirth in women previously treated for HL
[53]. Furthermore, Hill et al [53] found that women with a history of HL had an increased
relative risk to other parous women if they delivered within 60 months after HL therapy.
This risk is thought to be related to increased production of prolactin and lactation which
promote mammary carcinogenesis after radiation. To determine the hormonal influence
among the cases and controls, treatment variables of chemotherapy and radiation were
collected, as well as age of menarche, menopause, history of pregnancy and use of
hormonal therapy.
Family History
Hodgkin lymphoma occurs within families, and siblings of HL patients have an
increased risk of developing the same cancer [3]. The family history of women who
developed a second cancer after HL has been reviewed to determine if the family history
is significant for the development of secondary breast cancer. It has been hypothesized
that HL survivors with a family history of breast cancer have a higher risk of developing
secondary breast cancer and suggest the presence of cancer predisposing genetic risk
factors. In a case-control study of HL survivors treated prior to 30 years, a positive family
history of breast or ovarian cancer in a first or second degree family resulted in a 2.5 fold
increased breast cancer risk [53]. Furthermore, it has been suggested that a family history
of breast or ovarian cancer influences one’s response to radiation therapy leading to the
development of breast cancer. Hill et al. [53] found that the combined effect of a breast or
ovarian family history and increasing radiation dose does not exceed that of women
without this history and may be lower. These findings may be more relevant to the age of
radiation exposure to the young breast than the cumulative factor of family history and
radiation dose. There may also be ascertainment bias in obtaining the breast cancer
history in HL survivors with secondary breast cancer in comparison to controls.
In documentation of family history, several studies find that family cancer history
is more significant [18, 43, 53] than breast cancer history alone. A study by Nichols et al
[18] identified a cohort of Hodgkin survivors and found 21% (11 of 52 patients) with a
positive family history of cancer to have developed a secondary breast cancer. Family
history in this study included the proband and two other relatives with cancer over 2
generations in the paternal or maternal lineage. This cohort was compared to another
cohort of Hodgkin survivors without a secondary cancer and found to have only 4% (3 of
68 patients) with a positive family history of cancer. The study concluded that a subset of
HL survivors with a positive cancer family history will have a higher incidence of
secondary tumors than those without a cancer family history [18]. A more recent study
examined the risk of a secondary cancer among lymphoma patients with a family history
of cancer [43] and found an increased relative risk of breast cancer among HL survivors
with a positive family history of cancer. It was suggested that this family history presents
risk associated with DNA disrepair, shared environment, or interaction. To determine the
prevalence of breast cancer and familial cancers among the study cases and controls, a
two generation family history of both maternal and paternal lineage was obtained.
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Other Breast Cancer Risk Factors
The consumption of alcohol has been associated with breast cancer risk in both
pre- and postmenopausal women [55]. There are several mechanisms through which
alcohol is thought to increase breast cancer risk. Alcohol may act through its first
metabolite, acetaldehyde, leading to procarcinogen activation [56] or increase estrogen
levels in both pre- and postmenopausal women [57, 58]. Alcohol also affects the
synthesis of nutritional supplements including folate, pyridoxal phosphate (methyl group
synthesis and transfer), vitamins B12, D, A, E, retinoids, zinc, and selenium. These
nutritients are essential in amino acid metabolism and response to oxidative stress and
DNA repair[59] which when depleted enhance carcinogenesis [56]. The use of alcohol
was not collected on the cases and controls due to the concern for the lack of recall prior
to the onset of breast cancer and ascertainment bias in the cases. Other contributing breast
cancer risk factors include dietary fat, physical activity, body mass index (BMI).
Characteristics of Secondary Breast Cancer
Women at greatest risk for secondary breast cancer are those who receive
treatment for HL prior to 30 years of age [7-9]. The onset of secondary breast cancer after
radiation is 15-20 years, occurring 20 years prior to the median age of onset among the
general population [3, 5, 7]. The characteristics of the disease and axillary nodal status
are important in determining the long term prognosis. Women who develop secondary
breast cancer may have histories of atypical breast hyperplasia or high mammographic
density which confers a 3-5 fold excess risk of breast cancer [53] and a ninefold increase
if the women also has a family history of breast cancer [49]. In addition, hormone therapy
users within the general population are more than twice as likely to have high risk breast
density on mammography in comparison to non-users [60]. Therefore, history of atypical
breast disease or high mammographic breast density should indicate the need for diligent
screening and counseling. In addition to these clinical findings, the breast cancer
histological features, stage, and hormone receptors of HL survivors are similar to those in
the general population [3]. Furthermore, these women commonly present with tumor of
the medial breast and ductal carcinoma in situ. Lastly, secondary breast cancer presents
as bilateral disease in 10-30% of the breast cancer cases, while bilateral presentation is
only seen in 4-6% of the sporadic breast cancer cases [3].
Candidate Germline Mutations
Common germline mutations associated with familial breast cancer syndromes
such as ATM, TP53, BRCA1 and BRCA2 became candidate genes for explanation and
examination within the HL survivors with secondary breast cancer. One of the first
germline mutations to be examined was the heterozygous inactivating mutation in ATM,
the gene defective in ataxia-telangiectasia and associated with defective DNA repair
mechanisms and the development of cancer. The study used a protein truncation assay
with 52 patients who had a second cancer after treatment for HL. Mutation of the ATM
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gene was not found to occur in excess frequency among these survivors with second
cancers [18]. Variants within the ATM gene have also been considered. Thirty-seven
women with breast cancer after HL disease were matched for age at diagnosis and year of
diagnosis with 27 women after HL without breast cancer; heterozygous proteintruncating or missense mutations of ATM were again not associated with second cancers
[61].
Mutations in the familial tumor suppressor genes, TP53, BRCA1, and BRCA2
have also been explored [19]. Analysis of Hodgkin survivors with secondary cancers
including breast have been conducted. Mutational analysis using genomic DNA was
completed on 44 patients for the presence of the TP53 germline mutation. Nineteen of the
survivors with secondary breast cancer were also surveyed for presence of the BRCA1
and BRCA2 germline mutations. Importantly, the study was unable to locate germline
mutations that have been associated with the development of cancer, specifically TP53,
BRCA1, or BRCA2 [19]. To further examine a possible mutation of the BRCA1 and
BRCA2, loss of herterozygosity of these genes was evaluated but was not found [62].
This has led researchers to speculate that second cancers among HL survivors is a result
of inactivating germline mutations in other DNA repair genes not yet identified that
interact with TP53, BRCA1, and BRCA2 [18, 62].
Candidate Polymorphisms
Because the surveillance of leading candidate genes has not provided insight into
the etiology of secondary cancers, the focus has shifted to candidate polymorphisms. The
study of common population polymorphisms of drug metabolizing enzymes has become
an area of interest, most specifically those of the glutathione-S-transferase (GST) [20, 21,
63]. It is hypothesized that a homozygous genetic deletion of the null genotype of (GST)
M1 and P1 may impair the detoxification of environmental genotoxins or chemotherapy
resulting in a secondary malignancy [21]. The Childhood Cancer Survivor Study (CCSS),
a multi-institutional study group conducted a longitudinal study on 14, 054 survivors of
childhood cancer and explored the possibility of gene polymorphisms within the GST and
XRCC1, a key member of the base excision repair, as contributing to second cancers
among HL survivors [7]. From this data base, 650 Hodgkin survivors submitted buccal
cell specimen for GST study. The results suggested a modest possible role of the GSTM1
null genotype, loss of function, in the development of secondary cancers; however, the
effect was only significant when the GSTM1 and GSTT1 were considered together [7].
The study also examined the polymorphism of XRCC1 which participates in DNA strand
break repair and is important in radiation therapy recovery. The results were not
statistically significant but suggested that the presence of 1 codon 399 glutamine allele
provided protection against thyroid carcinoma and a slight increase in secondary breast
cancer. The CCSS research suggests that individual sensitivity may be a result of multiple
gene interactions or complexes [7].
Research supports that highly penetrant mutations such as BRCA1 and BRCA2
are associated with only 5% of primary breast cancer occurrences [64]. Therefore,
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investigators have hypothesized that the expression of less penetrant functional
polymorphisms combined with environmental interactions are associated with the
majority of disease. While candidate polymorphisms have been evaluated according to
their biochemical and physiological pathways, there appears to be multiple gene
interactions that may play a role in breast cancer onset. A recent study explored the
association of primary breast cancer with individual genes and with two- and three- gene
combinations. The study enrolled 1,716 women with primary breast cancer and 4,435
controls to explore single gene polymorphisms in genes known to be associated with
breast cancer. The findings were significant for two-and three-gene combinations
suggesting an interaction of genes and the development of breast cancer [64]. While this
study was conducted with primary breast cancer patients, it suggested the need for an
exploratory study of gene expression and associated polymorphisms in determining gene
to gene interaction. This is the approach of this study of women after secondary breast
cancer. While the etiology of secondary breast cancer among HL survivors is not the
result of a single variable, the cited literature describes both primary and secondary breast
cancer as resulting from multiple events or interactions. Thus far, the candidate genes and
polymorphisms can not fully explain the multiple event or interaction. The hypothesis
guiding this study was intended to could give additional insight into the interaction
between treatment variables and inherent characteristics, genetic polymorphisms, of the
individual and the role in development of secondary breast cancer.
Testing Methodologies
From the reviewed literature, determining the etiology of secondary breast cancer
using a candidate gene approach has not been successful [18, 19, 61, 62]. Additionally,
studies have found only weakly associated polymorphisms with an underlying etiology
that is polygenic [20, 21, 63, 64]. The candidate gene and polymorphism approach has
given limited information into the inherent predispositions; therefore, it is reasonable to
undertake an exploratory study to describe and compare the whole genome expression
and genotype of HL survivors with secondary breast cancer compared to those without
secondary breast cancer. A case-control design was used in the current study and is one
of two basic experimental designs used with gene-association studies [65]. This design is
an emerging methodology to examine gene-environment interactions in populations with
small sample sizes. The difference in global gene expression between groups was
measured with the Affymetrix GeneChip® Human Genome U133 Plus 2.0 Array. The
difference in genotype between groups was measured by the presence of single
nucleotide polymorphisms (SNP), between groups with the Affymetrix GeneChip®
Human Mapping 500K Set. Combined these analyses were compared to determine the
significant global gene expression and genotype differences between the two groups.
After determining significant differences between the case and controls, the genotype and
global gene expression of only the women with secondary breast cancer were examined
to determine candidate genes associated with genotype allele frequency.
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Microarray Technology
The technology of microarray analysis has exploded over the last 10 years, with
this research technique being applied to numerous studies of medical and clinical
relevance [66]. High-throughput microarray technology provides major areas of genomic
exploration: genome-wide analysis of gene expression, SNP genotyping, copy number
variants, transcript mapping, and resequencing [67]. This technique can now genotype
drug metabolizing enzyme genes, resequence tumor suppressor genes, and classify cancer
by differential gene expression and prognostic indicators. A number of studies have
identified prognostic and predictive ‘gene’ signatures as prognostic indicators in the
treatment of breast cancer [24]. Most of the early work with microarray analysis and
primary breast cancer has been done with tumor samples taken at the time of surgery.
These analyses have enabled researchers to analyze breast tissue and obtain a better
understanding of the molecular characteristics and clinical behavior of breast cancer. This
has been most helpful in the analysis of gene amplification and coamplification in
prognosis and treatment of breast cancer [25] . Examination of breast tissue will give
expression at the site of the disease, but will not give a global picture of the gene
interaction that may have predisposed individuals to multiple cancers. With the
hypothesis that the second cancer is the result of an inherent gene-gene/environment
interaction, peripheral blood was the sample used for the global gene expression and
genotype.
The Affymetrix GeneChip® Human Genome U133 Plus 2.0 Array used in this
study analyzes the expression level of over 47,400 transcripts and variants including
38,500 human genes. The array is comprised of over 54,000 probe sets and 1,300,000
distinct oligonucleotide features [29]. Microarray analysis allows genomic measurement
of an individual’s gene expression under a variety of genetic and environmental
conditions and may best capture biological phenomena through the interaction of
multiple genes. This gene expression is typically measured as an up or down regulation
of genes/gene pathways associated with the studied phenotype. This analysis has been
used to study and compare healthy and diseased samples, using the steady state mRNA to
infer maladaptive changes associated with disease. The earliest method was fold-change
which is a metric for comparing a gene’s mRNA expression between two experimental
conditions such as case-control. The challenge with fold change has been generalizability
of findings with arithmetic definitions differing between investigators. While these
studies have made it possible to compare the expression levels for active genes,
challenges remain most specifically with study design, inference, gene classification, and
validation [68].
Single nucleotide polymorphism (SNP) analysis was performed using the
Affymetrix GeneChip Human Mapping 500K set. This assay comprises two arrays
designed for high throughput parallel genotyping of ~500,000 SNPs that span the human
genome with a median intermarker distance of 2.5 kb [29]. The sequence of each allele is
determined using 24 probes that interrogate the forward and reverse strands at six
positions across each SNP. Genotype calls generated from the 500K Mapping assay
(500k_datasheet.pdf) [29] are highly concordant (HapMap agreement, 99.3%) and
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consistent (Mendelian consistency, 99.9%). Overall, 85% of the genome is represented
within 10 kb of a SNP. Further, with a mean allele heterozygosity of 0.30 across a wide
range of populations and ethnicities, the Mapping 500K set is well-suited for genotype
analysis within diverse ethnic groups.
The global gene expression from the Affymetrix GeneChip® Human Genome
U133 Plus 2.0 Array was combined with the SNP genotype from the Affymetrix
GeneChip Human Mapping 500K set in an association analysis. The SNP array data also
anlyzed for amplification, deletion, or no change in copy number. The expression data
were treated as quantitative phenotype and the analysis screened the in silico copy
number of the most significant SNP’s and found an association with the expression of a
list of genes and pathways. An understanding of the gene expression may bring an
understanding to the pathways that connect the genotype to the cellular traits [69] and a
better understanding of the biological processes driving the association between
expression and response.
Summary of Review
The reviews of literature describe known risk factors associated with secondary
breast cancer among HL survivors and include radiation, chemotherapy, age, time from
diagnosis, hormonal influence and family history. While the radiation dose has been
implicated as a significant risk factor, the risk is inclusive of all who are treated with
chest radiation exposure regardless of treatment dose. The age of radiation exposure
before 30 years has clearly been established as a risk factor, which would include all
pediatric female HL survivors. Additionally, the time from exposure has been cited as
being greatest at 15-20 years post therapy; however, these women continue to have an
increased absolute and lifetime risk. Administration of alkylating agents has been
associated with a decreased breast cancer risk; however, the timing of alkylating
exposure in the pediatric population may not be protective. Perhaps pelvic radiation is the
most productive endocrine insult, leaving the question and unclear association of
hormonal supplementation in HL survivors. The hormonal influence of pregnancy within
60 months after HL therapy has been found to be associated with an increased breast
cancer risk and should be discussed with survivors. Lastly, the family history of not only
breast cancer, but familial cancer should be reviewed with all HL survivors. The review
of risk factors attempt to assist the clinician in identification of survivors at greatest risk
for secondary breast cancer. However, it is my assumption that the pediatric HL patient is
a vulnerable host due to radiation exposure of growing, immature cells and all are at an
increased risk of secondary cancers. Therefore, this study was directed at exploration of
inherent factors that impede the DNA repair, facilitate hormonal exposure, or prevent
apoptosis leading to the development of secondary breast cancer.
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CHAPTER 3. METHODS
Research Design
Research Design and Study Population
This descriptive cross-sectional case-control study assessed the gene expression
and genotype profile of women who are survivors of childhood HL (see Figure 3.1). The
first group (cases) included women who were treated with mediastinal radiation and
developed secondary breast cancer. The second group (controls) included women who
were treated with mediastinal radiation and have not developed secondary breast cancer.
The study definition of breast cancer was the development of documented breast
cancer after treatment for pediatric HL, which included mediastinal radiation. Estimates
regarding the timing of the second cancer range from 15-20 years after radiation exposure
[1-2], The study definition for non-breast cancer was the absence of breast cancer and a
negative mammogram within one year of study.
Eligibility Criteria for Case and Control Participants
•
•
•
•
•

•
•

Females treated for pediatric HL at St. Jude Children’s Research Hospital
between 1970 to 1991
18 to 55 years of age
Cases had documented breast cancer prior to 51 years of age
Controls had documented negative mammogram within one year of participating
in the study
Controls matched treatment variables of the breast cancer case and
included: age at diagnosis, mantle/mediastinal radiation dose, para-aortic/splenic
radiation dose, alkylating agents dose (cyclophosphamide and procarbazine), and
time since diagnosis of HL
English-Speaking
Written consent for participation

Exclusion Criteria
•
•
•

Confirmed diagnosis in the control group of any secondary cancer
Treatment within the last 6 months for any cancer, excluding basal and/or
squamous cell carcinoma, in the case group
Inability or unwillingness of research participants or legal guardian/representative
to give written informed consent
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Hodgkin Lymphoma Treated with Radiation Therapy

Development of Breast
Cancer (Case) n=13

Non-Development of Breast
Cancer (Control) n=36

Figure 3.1 Study Design.
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Procedures for Accomplishment of Aims
Case and Control Participation
The case/controls were taken from the data base of active alumni who were
treated for pediatric HL at St. Jude Children’s Research Hospital (SJCRH) between July
1970 and July 1991. After obtaining Institutional Review Board approval (XPD05-108),
a retrospective chart review was conducted and found 440 persons treated for pediatric
HL within these years, of which 190 are women and 19 (10%) of these women
subsequently developed secondary breast cancer. Of the 19 women with secondary breast
cancer, 13 women were identified as survivors of secondary breast cancer after HL. All
surviving secondary breast cancer patients (cases) were asked to participate in the study,
while the control participants were selected based on controlling variables from the
treatment characteristics. Once the cases were identified, the protocol was submitted for
approval from the SJCRH and University of Tennessee Institutional Review Board
(Appendix A).
The 13 HL breast cancer survivors are the study cases and were matched with 3
controls, based on power estimates as discussed in the statistical section. In identifying
the controls, 101 women were eligible as controls and were randomly selected by the
study biostatistician after matching on the variables of age at diagnosis,
mantle/mediastinal para-aortic and pelvic radiation dose, alkylating agent
(cyclophosphamide and procarbazine) dose, and time since HL diagnosis. These variables
were classified into classes based on Low/None, Medium and High groups. This led to no
match for four cases. Since the list of the controls was limited in matching with all cases,
the median cut-off for age at diagnosis and time since diagnosis was used. The final age
classes were age < 14.7608 years (Age Dx Class =1) and age >= 14.7606 (Age Dx Class
=2) and time since diagnosis < 27.8696 years (Time Dx Class =1) and time since
diagnosis >=27.8696 (Time Dx Class=2). The dose of maximum chemotherapy was then
calculated ‘Max Chemo’ dose based on the maximum doses of Cyclophosphamide and/or
Procarbazine patient received. This chemotherapy dose was defined as high and low dose
of Max Chemo dose using a cut-off <7000 mg (Max Chemo Class =1) and >= 7000 mg
(Max Chemo Class=2). Similarly, the dose of radiation was calculated using the same
analogy as for Max Chemo class to define Max Radiation Class, where Max Radiation
Class =1 when Max Radiation < 30 Gy and Max Radiation Class=2 when Max
Irradiation >=30 Gy and Max Irradiation is the maximum amount of radiation patient
received at Mantle, Mediastinum, Paraarortic and/or Pelvic. When more than 3 possible
controls were available for each case, simple random sample was used to select controls.
The controls were matched on variable significance with the most important being
radiation dose, then chemotherapy, time since diagnosis, and age at diagnosis
Of the 13 cases, one was treated on HOD 68, four cases were treated on HOD 72, five on
HOD 80, one on HOD 90 and two according to best clinical management. Eight of the
cases received alkylating agents, while four were treated with radiation alone. The dose
of mantle/mediastinal radiation ranged from 39-20Gy. The controls were treated with
similar doses of chemotherapy and radiation according to their matched case. If a control
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was not located or unable to participate, the biostatistician continued the randomization
of controls, this process was repeated as needed until all matched controls were
considered. If a control was found to be a case, the control was reclassified as a case and
matched with 3 controls.
Once the cases and controls were identified, eligible participants were discussed
with the SJCRH alumni physician. An introductory letter (Appendix B) and consent form
(Appendix C) was mailed to the eligible participants explaining the purpose of the study
and requirements of obtaining demographic information (Appendix D) and a blood
sample. Two weeks after receiving the letter, each eligible participant received a followup phone call from the primary investigator (PI), who responded to questions and
obtained verbal consent for completion of a demographic health questionnaire over the
phone. After the participant gave verbal consent for the study, the demographic questions
were reviewed and responses from each participant recorded by the PI for validation
accuracy. The demographic responses were recorded and categorized; accuracy of
extraction and categorization were verified for inter-rater reliability with another
researcher with 98% agreement between raters. Written consent was obtained from all
participants and returned to SJCRH. Once this consent was received, each participant
was officially entered on study and mailed a kit for blood collection. To enhance the
scope of future research of HL and secondary cancers, a biological repository consisting
of stored blood (DNA, serum phase) from all participants was discussed with each
participant and written consent was obtained for those agreeing to participate in the
biological repository. The stored DNA sample was obtained from the initial 7mLs of
blood collected in the EDTA tube.
Enrollment of Cases and Controls
Ten of the 13 known survivors of secondary breast cancer were initially enrolled
on study. Three of the survivors were lost to follow-up; however, it was later learned that
one of these lost to follow-up had died within the previous two months secondary to
bacterial colitis. The matched controls to these 10 cases were then contacted for
enrollment. Telephone contact with these controls found two additional Hodgkin
survivors with secondary breast cancer. One had developed breast cancer within the
previous 6 months, while the other had been diagnosed within the month and had
received no breast cancer therapy. These women were then enrolled as cases and 3
controls were matched for each. A study packet was sent to all potential controls with
follow-up telephone contact. The number of participants who gave consent, were
ineligible, declined, or who were lost to follow-up from the initial case control matched
variable randomization are included in Table 3.1.
Fifty one controls were contacted, with 34 found to be eligible and consenting to
participate. Two agreed to participate, but were ineligible due to a secondary basal cell
carcinoma and another due to pregnancy secondary to gene expression associated with
pregnancy. Another who was consented and enrolled on study was not included in the
demographic analysis due to subsequent development of hepatocellular carcinoma but
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Table 3.1 Initial Control Contact for 12 Matched Cases.
Control Participation

Responses

Controls contacted via mail or phone

n=51

Consented

n=34

Ineligible at time of contact

n=2

Declined

n=3

Lost to follow-up

n=12
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was included in the expression and genotype analysis. Three declined participation due to
time conflict in arranging blood collection and 12 were lost to follow-up. A total of 34
controls were enrolled from the initial case-control matching, with 33 meeting all
eligibility criteria. The list of potential controls was reviewed for additional participants
on the criteria of radiation dose and chemotherapy as previously described. Three
additional controls were identified and matched as described, with one consenting (35
controls) to study and two lost to follow-up. No other controls were matched to the cases
on the variables of radiation and chemotherapy dose.
Approximately 6 months after the study began, the 13th case was reported to the
SJCRH database and this survivor was subsequently enrolled. In matching on race
(African American) and disease variables, only three controls were identified with one
consenting and two lost to follow-up. This resulted in 13 cases and 36 controls. Ten cases
have 3 matched controls per case, 2 cases have 2 matched controls per case, and the last
case described had only 1 matched control.
Blood Collection for RNA and DNA Extraction
Sample collection was discussed with each participant and arrangements were
made accordingly. The samples were collected at SJCRH, an affiliate clinic, local
physician’s office, or at the participant’s residence. Samples were collected by a
registered nurse, technician, or physician designee. Collection supplies and instructions
were provided to those responsible for blood collection. Instructions regarding overnight
mailing and shipping procedure were also outlined. No cost to the participant was
associated with the blood collection. Risks associated with the venipuncture were shared
with participants and included the possibility of bruising at the venipuncture site.
For RNA extraction, 5 milliliters (mL) of blood were collected directly into two
2.5mL PAXgene™ Blood RNA System (Qiagen, Valencia, CA). The PAXgene tube
contains a reagent that stabilizes intracellular RNA by reducing RNA degradation. The
blood was collected into the PAXgene tube according to manufacture’s instruction. After
collection, each tube was inverted 10 times and stored in an upright position for a
minimum of two hours at room temperature to allow for incubation. At the completion of
incubation, samples were stored on ice for shipment to SJCRH. The samples were stored
at -20ºc for a minimum of 24 hours and then transferred to a non-frost free freezing unit
an stored at -80ºc until processing.
For DNA extraction, 7 mLs of whole blood was collected in tubes containing
EDTA as an anticoagulant. The blood sample was mixed and placed on ice for shipment
to SJCRH. If the sample was not immediately processed, the sample was stored at 4º for
up to 72 hours.
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RNA Extraction
The RNA extraction was performed under the Processing Clinical Samples for
DNA, RNA, Protein and Cryopreservation Procedures Manual within the Department of
Pharmaceutical Sciences at SJCRH. Samples collected for RNA extraction were removed
from the -80ºc freeze and placed in a 37ºc water bath for a quick thaw. In the lab, the
RNA was extracted using the TRI REAGENT® protocol. After thawing, the tubes were
centrifuged for 10 minutes at 5000xg (gravitational acceleration) using a swing-out rotor
at room temperature. After centrifuge, the supernatant was decanted and discarded. Five
mL. of RNase-free water was added to the pellet. The pellet was resuspended into
solution and transferred to an 8cc polypropylene tube and capped. The tube was
centrifuged for 10 minutes at 5000xg in a swing-out rotor at room temperature. After
centrifuge the supernatant was removed. Two mL of TRI reagent was added and mixed
well with the pellet. The TRI reagent was allowed to digest for 5 minutes. The
homogenate was then supplemented with 0.4 mL chloroform (0.2 mL for 1mL of TRI
reagent) and vortexed for 15 seconds. The mixture was stored at room temperature for 5
minutes and then centrifuged at 12000 rcf for 15 minutes at 4ºc. A sterile transfer pipette
was used to transfer the colorless upper aqueous phase into a new tube. To the colorless
aqueous fluid, 1 mL of isopropanol (0.5 mL of isopropanol per 1 mL of TRI reagent used
in the initial homogenization) was added. The mixture was vortexed and stored at room
temperature for 5 minutes. The mixture was then centrifuged at 12000 rcf for 15 minutes
at 4ºc. The supernatant was discarded and the tube dried without disruption of the RNA
pellet. One mL of cold 75% ethanol was mixed with the pellet into solution and
transferred into a 1.5 mL microtube (Axygen). The pellet/ethanol mixture was
centrifuged at 10000 rcf for 5 minutes at 4ºc. The supernatant was discarded, leaving the
RNA pellet to which 10-15 mcl of RNase free water was added. The pellet and water
were mixed with 11 mcl of solution placed in a 0.5 mL microtube (Axygen). Both
microtubes were placed on ice, with the 0.5 mL microtube transported to the Hartwell
Center for processing. The remaining RNA solution was placed in an 80ºc non-frost free
freezer for disposal at the completion of the study. This system typically yields 4-10g
of pure RNA from 2.5 mLs of blood.
DNA Extraction
All buffers and reagents used in the extraction process were commercially
purchased in the QIAGEN Blood and Cell Culture DNA Kit. The 7 mL. blood samples
were transferred from storage and each was transferred to a 50 mL screw-cap labeled
tube. The lysis protocol began with 1 volume (7mLs.) of ice-cold Buffer C1 and 3
volumes (21mLs.) of ice-cold distilled water. The tubes were then inverted several times
and incubated in an ice bucket for 10 minutes. The Buffer C1 lyses the cells but stabilizes
and preserves the lymphocyte nuclei. The blood suspension becomes translucent due to
lysing of the erythrocytes and release of hemoglobin.
After ice incubation, the 50mL tube of lysed blood was centrifuged at 4ºC for 15
minutes at 1300xg. The blood suspension was poured off and the nuclear pellet was
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visible. Ten mLs of Buffer G2 was added into the tube and the tube was vortexed for 30
seconds at maximum speed, resuspending the nuclei. The resuspended nuclei was then
mixed with 200l of QIAGEN Protease and incubated in a 50ºC water bath for 60
minutes. The Buffer G2 and QIAGEN Protease work together in striping the genomic
DNA of all bound proteins, facilitating efficient DNA removal during purification.
Part II of the DNA extraction process was isolation of genomic DNA from the
nuclei. Prior to beginning this process, QIAGEN Genomic-tip 500/G was equilibrated
with 10 mLs of Buffer QBT and allowed to empty by gravity flow. Once the equilibration
buffer emptied from the genomic-tip, the sample was removed from the water bath and
vortexed for 10 seconds at maximum speed. This step prevents poor DNA flow rates due
to increased viscosity. The DNA was then filtered through the equilibrated genomic-tip.
Once the DNA completed gravity flow through the genomic-tip, 2 x 15 mL washings of
Buffer QC were filtered through the tip. These two washings are sufficient to remove all
contaminants in the majority of DNA preparations.
The QIAGEN Genomic-tip was then placed over a clean 30 mL collection tube
and the genomic DNA was eluted with a 15 mL washing of prewarmed Buffer QF. The
warming of the buffer increases DNA yield. To precipitate the DNA,10.5 mLs. of
isopropanol was added to the eluted DNA and centrifuged at >5000xg for 15 minutes at
4ºC.
Lastly, the DNA pellet was washed with 1 mL. of 70% ethanol, vortexed, and
centrifuged at >5000xg for 15 minutes at 4ºC. The supernatant was removed and the
DNA pellet was allowed to air dry in the tube for 5-10 minutes. The DNA was
resuspended in 1 mL of TRIS(TE) EDTA Buffer, ph 8.0. DNA dissolves best under
slightly alkaline conditions with a ph 8.0-8.5. To facilitate the concentration
equilibration, the suspension was transferred to a microcentrifuge tube and placed on a
rotator (Labnet labroller) overnight.
After the DNA samples were rotated overnight, the concentration of each was
determined with the technique of PicoGreen® ultrasensitive fluorescent nucleic acid stain
use for quantization of double-stranded DNA (dsDNA) in solution protocol. After the
DNA concentration for each sample was determined, 50 nanograms (ng) of each sample
were run on an electophoresis gel at a concentration of 0.8% with High DNA Mass ™
Ladder by Invitrogen. High DNA Mass™ Ladder is suitable for estimating the mass
(quantity) of unknown DNA samples by ethidium bromide staining. This ladder consists
of an equimolar mixture of six blunt-ended DNA fragments of 10, 6, 4, 3, 2, and 1 kb.
Electrophoresis of 4 l of the High DNA Mass™ Ladder results in bands containing 200,
120, 80, 60, 40, and 20 ng (520 ng total) of DNA, respectively. The gels were run at 75
volts for 180 minutes. At the completion, each gel was removed and placed in the
Fotodyne transilluminator and camera and analyzed with the Fotodyne Electrophoresis
Gel Analysis Software. This software program provides quantification of the sample
through the use of the High DNA Mass™ Ladder and provides an accurate molecular
weight and DNA quantity calibration. After each sample concentration was determined,
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250ng of DNA was plated into a 96 well plate for Nsp analysis and 250ng of DNA was
plated into a 96 well plate for Sty analysis and forwarded to the Hartwell Center.
Measurement of RNA: Quality Control
The purity and quantity of RNA was measured using a Spectromax Plus 384
spectrophotometer. The OD260 values were used to quantify the concentration, while the
OD260/280 ratios were used to assess the purity of the RNA sample. OD260/280 ratios
between 1.9 and 2.1 indicate high purity of RNA; ratios <1.8 were associated with
protein contamination, while ratios >2.1 indicated carryover of small oligonucleotides
and nucleotides. RNA quality was also evaluated with an Agilent 2100 Bioanalyzer. An
electrophoresis profile generated by an Agilent analysis was used to calculate the relative
abundance of the 28S and18S ribosomal RNAs which are surrogate markers of mRNA
degradation. A ratio <2.0 indicated RNA degradation which can also be seen as
fragments running ahead of the 18S species. RNA samples that passed these quality
control measures were processed for Affymetrix GeneChip analysis. Five samples did not
pass these quality control measures and the additional PAXgene tube was extracted for
RNA and resubmission to the Hartwell Center for quality control and processing. All five
passed quality control upon the second process.
Processing of Extracted RNA: Hartwell Center, SJCRH
As discussed, gene expression analysis was performed using the Affymetrix HGU133Plus2 GeneChip array. RNA samples were processed using the Affymetrix
Eukaryote Two-Cycle Target Assay (www.affymetrix.com/support/technical). In the
process, 100 ng of total RNA was used as starting template for cDNA synthesis. The
RNA was annealed to a T7-oligodT(24) primer containing the recognition site for the
bacteriophage T7 RNA polymerase. A first cycle of cDNA synthesis was accomplished
using the SuperScript II cDNA synthesis kit according to the manufacturer’s conditions
(Invitrogen). The resulting cDNA was then used as template for generating antisense
cRNA using the MEGAscript T7 in vitro transcription kit (Ambion). The purified cRNA
(400 ng) was then primed with random hexamers to initiate a second cycle of cDNA
synthesis. The second round cDNA was then used as a template to generate biotin-labeled
cRNA using the Affymetrix GeneChip In Vitro Transcription labeling kit. Twenty
micrograms of biotin-labeled cRNA was fragmented by heating and metal induced
hydrolysis and added to a hybridization cocktail containing probe array controls and
blocking agents (BSA and herring sperm DNA),then incubated overnight at 45° C on a
GeneChip array. Following hybridization, the arrays were washed automatically using a
GeneChip Fluidics Station 400 under high stringency conditions to remove nonhybridized labeled cRNA. To detect bound target, arrays were stained with Streptavidin
Phycoerythrin (SAPE, Molecular Probes), washed again, and then scanned using the
Affymetrix GeneChip Scanner 3000.
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Expression signals for each transcript were calculated by the MAS5 statistical
algorithm using the Affymetrix GCOS software (version 1.4). In this method, the global
signals on the array were scaled to a 2% trimmed mean of 500. Detection calls (Present,
Absent or Marginal) were determined using the default parameters of the software and
recommended by the Affymetrix GeneChip protocol.
Processing of Extracted DNA : Hartwell Center, SJCRH
DNA samples submitted for SNP analysis were processed according th the
Affymetrix protocol (affymetrix/500k_assay_manual.pdf). Total genomic DNA (250 ng)
was digested with a restriction enzyme (10 units of NspI or StyI, 2h at 37 C), and then
ligated to adapters that recognized the cohesive four bp overhangs (800 units T4 DNA
ligase, 0.75 uM adapter, for 3 hours at 16°C). Each adapter contained a unique sequence
that permited amplification by using a single PCR primer. The ligated DNA was
amplified using thermocycling conditions (5 uM primer, 1X Clontech TITANIUM Taq
polymerase; 30 cycles of 30 sec at 94°C, 30 sec at 60°C, 15 sec at 68°C) that enriched
restriction fragments from 250bp to 1100 bp in size. This selective reduction in genomic
complexity is key to the success of the mapping array. Following PCR, 90 ug of
amplified DNA was fragmented to 25-100 bp by digestion with DNase I (0.25 units
enzyme, 35 min at 37°C), end-labeled with 857 uM biotinylated-nucleotide using
terminal deoxynucleotidyl transferase (105 units enzyme, 4 hours at 37°C), was added to
a hybridization cocktail containing probe array controls and blocking agents (human Cot1 and herring sperm DNA). This mixture was then incubated overnight at 48°C on a
GeneChip array. After hybridization, arrays were washed automatically using a
GeneChip Fluidics Station 400 under high stringency conditions to remove nonhybridized labeled DNA. Arrays were incubated with Streptavidin Phycoerythrin (SAPE,
Molecular Probes), washed, and then incubated with biotin-conjugated anti-streptavidin
antibody. After removal of the antibody solution, the arrays were re-stained using the
SAPE, washed again, and then scanned using an Affymetrix GeneChip Scanner 3000.
Genotype calls are initially determined using the Affymetrix Genotyping
Software (GTYPE) version 4.0. The GTYPE software uses a dynamic model algorithm to
call genotypes on an array by array basis. After processing the complete set of samples,
genotype calls were generated using the BRLMM algorithm (also available within the
GTYPE software). The BRLMM method [70] uses a multi-chip analysis algorithm which
provides superior accuracy and consistency of calls as compared to the GTYPE
algorithm.
Statistical Procedures
The study is based on a case-control design. The cases include 13 survivors and
for each case there are three matched controls. This 1:3 matched case control design
gives an efficiency of 75% for binary measures [71], an increase of 25% from a 1:1
match. Controls were matched to cases based on the previously described variables
including; mantle/mediastinal radiation dose, para-aortic/splenic radiation dose,
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alkylating agent dose (cyclophosphamide and/or procarbaine), age at initial diagnosis,
and time since HL diagnosis. In the surviving patients, 101 controls were identified and
stratified based on the matching characteristics from which 3 controls from each stratum
were randomly selected. If a control declined participation another control was randomly
selected from the stratum of matched controls. During the study if a control became a
case, three matched controls (one for the original case and two for the new case) were
randomly selected. It was proposed the study would take approximately 18 months. All
data were collected and ready for analysis approximately 13 months after opening the
study.
Statistical analyses for specific aims are outlined as follows:
Primary Aim One
Assess whether global gene expression profiles differ between two groups of
radiated pediatric female Hodgkin lymphoma survivors with and without the
development of secondary breast cancer.
Affymetrix U133 Plus 2.0 arrays were utilized to measure extracted RNA gene
expression in blood samples taken from both the cases and controls. Normalized gene
expression signals were computed using Affymetrix MAS 5.0 software. The normalized
signals were log-transformed prior to subsequent statistical analysis [72]. For each probe
set, the two-sided Wilcoxon rank sum tests were used to compare the mean/median
expression of the cases to that of the controls. To account for multiple testing, the set of
resulting p-values was used to estimate the false discovery rate (FDR) with a robust
method [73].
Gene-set enrichment analysis was performed with a structured permutation
approach [74]. Affymetrix-defined pathways were used to define gene sets and the
negative sum of Wilcoxon p-values was used as the gene-set statistic. The significance of
the gene set statistic was determined via 10,000 permutations.
Primary Aim Two
Assess whether genotype profiles differ between two groups of radiated
pediatric female Hodgkin lymphoma survivors with and without the development of
secondary breast cancer.
Affymetrix GeneChip® Human Mapping 500K Set was used to characterize the
genotype of each case and control. The BRLMM algorithm [70], as implemented in
Affymetrix software, was used to generate a genotype call (AA, AB, BB, or NoCall) for
each of the 500K SNP markers and each sample.
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First, markers with low genotypic variability were removed due to statistical
futility prior to subsequent analysis. For each of the remaining SNPs, the association of
genotype with case-control status was explored with a chi-square test. To adjust for
multiple-testing, the resulting p-values were used to estimate the FDR with a robust
method [73] .
Additionally, the data were used to test for association of full-gene genotypes
with case-control status using a structured permutation approach [74]. SNPs were
mapped to genes on the basis of physical location relative to the start- and stoptranscription positions. SNPs between the start- and stop-transcription positions or within
5,000 base pairs of the start- and stop-transcription positions were mapped to the genes.
The negative sum of log-p-values from the asymptotic chi-square test was used as a
statistic summarizing the significance of each group of SNPs mapped to a specific gene.
The significance of the SNP-set statistic was determined via 10,000 permutations. The
method of Benjamini and Hochberg [75] was used to compute FDR-adjusted p-values
[76].
Primary Aim Three
Identify potential candidate genes through identifying copy number
variations that associate with the risk of secondary breast cancer.
For each SNP marker, summary signals were computed using dChip SNP
software [77]. These signals were subsequently reference normalized [78]. Fore each
marker, the median and inter-quartile range of signal values across controls was
computed. Then, for each subject, a standardized difference was computed for each
marker by subtracting the median among controls and dividing by the inter-quartile range
among controls.
A Bayesian segmentation algorithm [79, 80] was used to segment the
standardized difference profile of each chromosome in each subject. Segments with fewer
than 25% of standardized differences being positive were identified as in silico regions of
loss and segments with at least 75% of standardized differences being positive were
identified as in silico regions of gain.
Finally, the segmentation results of individuals were used to segment the genome
into regions with distinct patterns of gain/loss across the entire cohort. For each region
with at least 5 subjects with an in silico gain or loss, we used Fisher’s test to explore the
association of in silico copy number with case-controls status.
Secondary Aim
Explore the association between lifestyle characteristics (hormone use,
pregnancy, lactation), family history and the occurrence of breast cancer.
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Descriptive analyses of cases and controls were conducted on the following
variables: age, age at Hodgkin diagnosis, years since HL diagnosis, radiation,
chemotherapy, age at menses, age of hormone initiation, age at menopause, age at first
pregnancy and time from HL diagnosis and first pregnancy. Two sample t test was used
to compute the p values.
Frequency tables were generated for menses status, use of hormone therapy and
status of pregnancy, and simple logistic regression was used to evaluate the association
between these variables and case-control status.
In addition, log-linear regression was used to evaluate the differences between
case and control in number of pregnancies and number of live births. This part of the
analyses was conducted using SAS version 9.1 (SAS Institute, 2003).
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CHAPTER 4. RESULTS
Introduction
Data obtained over the course of this study are presented in this chapter. The
results are presented according to the study aims.
Description of the Sample
Treatment Characteristics
The study sample consisted of 48 women, from whom blood was collected and
analyzed for global gene expression and genotype. The women who developed secondary
breast cancer (cases) were matched with women who did not develop secondary breast
cancer (controls) according to radiation dose, maximum alkylating chemotherapy dose,
age at diagnosis and time since diagnosis. The cases and controls were not statistically
different in current age, age at HL diagnosis and time since HL diagnosis as described in
Table 4.1. Treatment variables of mediastinal/mantel radiation and maximum dose of
alkylating chemotherapy were well matched. Total radiation dose was the most
significant matching variable and ranged from 41 to 20 Gy among cases with a median
dose of 35.5 Gy.; radiation dose for the controls ranged from 15 to 41.7 Gy with a median
dose of 35 Gy. Alkylating chemotherapy total dose was the second most significant
matching variable because the induction of premature menopause that is associated with
alkylating chemotherapy is thought to be a protective mechanism against the
development of breast cancer. Ten of the 13 cases (76.9%) received alkylating therapy;
24 of the 35 controls (68.5 %) received alkylating therapy. The cases and controls were
not matched on pelvic and/or para-aortic radiation; however, it is important to determine
this potential protective effect. Only 1 case (7%) received pelvic radiation and 8 cases
received para-aortic which would have a smaller radiation scatter to the ovaries. In
comparison, 16 controls (45.7%) had pelvic radiation of which 4 of the 16 received
combined para-aortic and pelvic radiation, 11 controls received para-aortic radiation, 7
controls received no pelvic or para-aortic radiation.
Reproductive and Family Characteristics
Each woman also completed a demographic form that included items regarding
her hormonal use, reproductive history, and cancer family history. Differences between
cases and controls on variables of menses, menopause, hormonal therapy, age at first
pregnancy, and time from HL to first pregancy are listed in Table 4.2. There were no
statistical differences between the cases and controls in the age of menses, current status
of menses, or use of hormonal therapy. There is a statistical difference in age of
menopause between the cases and controls, 16 controls (45.7%) who received pelvic
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Table 4.1 Demographic Data: Current Age, Age at Time of Diagnosis and Years Since
Diagnosis For Study Participants Who Did and Did Not Develop Secondary Breast
Cancer.

Age in yrs
(mean ± SD)
Age at Hodgkin
Diagnosis
(mean ± SD)
Years Since HL
Diagnosis
(mean ± SD)

Study Sample
n=48

With Breast
Cancer
n=13

Without
Breast Cancer
n=35

p value

40.2 ± 5.6

41.9 ± 6.7

39.6 ± 5.2

0.2181

14.3 ± 3.2

14.6 ± 2.1

14.3 ± 3.3

0.8127

26 ± 5.9

27.5 ± 5.2

25.4 ± 6.01

0.2722
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Table 4.2 Demographic Data: Age at Menses, Menopause, and Hormonal Use,
According to Study Participants Who Did and Did Not Develop Secondary Breast
Cancer.
Study
Sample
n=48

With Breast
Cancer
n=13

Without Breast
Cancer
n=35

P-value*

12.7

12.8 ± 1.4

12.7 ± 2.3

0.8387

Age at Menopause
(mean ± SD)

34

38.3 ± 2.5

32.1 ± 9.6

0.0191

Currently Having
Menses

Yes=20
No=28

Yes=4
No=9

Yes=16
No=19

0.3544

Use of Hormones
(mean ± SD)

48

13

35

NA

21.6

22.9 ± 6.5

21.1 ± 7.7

0.4995

32.6

32.8 ± 8.3

32.4 ± 7.7

0.9030

25.4

26.5 ± 3.5

24.9 ± 4.6

0.3508

10.6

11.4 ± 3.1

9.9 ± 5.0

0.3992

Age at Menses
(mean ± SD)

Age Started
Hormones
(mean ± SD)
Age Stopped
Hormones
(mean ± SD)
Age at 1st
Pregnancy
(mean ± SD)
Time from HL to
1st Pregnancy
(mean ± SD)
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radiation experienced the earliest onset of menopause with an average of 27.8 years of
age (range 16-40), while only 3 of the 16 continue (28.7%) to have menses. All of the
cases and controls reported hormonal use with no differences in the ages that hormones
were initiated or discontinued. There was no statistical difference in age at first
pregnancy or time from Hodgkin diagnosis and first pregnancy between the cases and
controls. Reproductive history outlined in Table 4.3 shows that overall 31 (64.5%) of the
cases and controls reported at least one pregnancy, with 76.7% of the cases becoming
pregnant and 60% of the controls becoming pregnant. Overall the cases and controls
reported 69 pregnancies and 53 live births with the controls having the highest number of
lost pregnancies. While the controls reported higher rates of pregnancy difficulties with a
lower number of pregnancies and live births; differences in reproductive history were not
statistically significant.
Family history of cancer was collected by self-report form the cases and controls.
Eleven of the 13 cases (84.6%) reported a family history of cancer in a first or second
degree family member. Five of the 11 (45%) cases reported among first degree relatives
included: breast, prostate, esophageal, and skin. Among these 11 cases, the most common
cancers among second degree relatives included: lung, breast, prostate, and lymphoma.
Thirty one of the 35 controls (88.5%) reported a family history of cancer in a first
or second degree family member. Fourteen of the 31 (45%) controls had a first degree
family member with cancer with breast being the most frequent followed by lymphoma,
skin, and lung. The most common cancers among second degree relatives included:
lymphoma, breast, and prostate.
Breast Cancer Characteristics Among Cases
For the women with breast cancer, histology and hormonal status of their breast
cancer was collected from pathology report if available or self report. In addition, a
retrospective chart review collected additional information related to breast cancer
occurrence including age at breast cancer diagnosis in comparison to Hodgkin diagnosis,
and time from radiation to diagnosis of breast cancer. The average age of secondary
breast cancer among the cases occurred at 36.5 ± 6.7 years of age with a range of 27.251 years of age. The time from radiation exposure to the development of secondary breast
cancer among the cases is 21.3 ± 5.8 years after radiation with a range of 12-34 years.
The range of 34 years is the result of an outlier and if excluded the range would be 12-27
years with a mean of 20.2 ± 4.5 years from radiation to the development of breast cancer.
There was no difference in the location of the breast cancer (right vs. left breast) and the
tumors were predominately infiltrating ductal carcinoma. The tumor estrogen,
progesterone, and HER-2 statuses are unknown in 3 of the cases. The location, histology,
and expression are detailed for each case in Table 4.4.
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Table 4.3 Demographic Data: Reproductive History According to Study Participants
Who Did and Did Not Develop Secondary Breast Cancer.
Study Sample
n=48

With Breast
Cancer
n=13

Without Breast
Cancer
n=35

P-Value
(95% CI)

Achieving
Pregnancy

31

Yes=10
No=3

Yes=21
No=14

Number of
Pregnancies
(mean ± SD)

69

1.5 ± 1.2

1.4± 1.4

0.7223
(0.492,1.393)

53

1.3 ± 0.9

1.0 ± 1.0

0.7223
(0.347, 1.101)

30

Yes=3
No=7

Yes=8
No=12

0.5934
(0.307, 7.872)

Number of
Live Births
(mean ± SD)
Breast Feeding

40

0.2827
(0.105, 1.931)

Table 4.4 Breast Cancer Characteristics.
Location of
breast cancer

Histology

Estrogen

Progesterone

Her-2

Bilateral

Adenocarcinoma:
Infiltrating ductal

+

-

-

Left Breast

Infiltrating ductal

Unknown

Left Breast

Infiltrating ductal

Unknown

Left Breast

Infiltrating ductal

+

+

-

Right Breast

Infiltrating ductal

+

+

-

Left Breast

Infiltrating lobular

+

+

+

Invasive ductal

-

-

-

Left Breast

Infiltrating ductal

+

+

+

Right Breast

Infiltrating ductal

-

-

Unknown

Right Breast

Infiltrating ductal

+

-

+

Left Breast

Adenocarcinoma

+

-

-

Right Breast

Ductal in Situ

Unknown

Left Breast

Infiltrating ductal

+

-

+

Right breast
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Primary Aim One
Assess whether global gene expression profiles differ between two groups of
radiated pediatric Hodgkin lymphoma survivors with and without the development
of secondary breast cancer.
The analysis identified 100 differentially expressed genes (p  0.0015; FDR 
0.68) and 12 pathways that showed significant gene-set enrichment (p  0.05; FDR 
0.57).
In an analysis that ignored matching of individual cases to their selected
controls using unmatched ranksum found genes of significance and 12 Affymetrixdefined pathways from 233 identified pathways with a statistical difference between
cases and control were observed. The pathyways of significance as well as the test
statistic, permutation p value for the pathway, and false discovery rate (q) are given in
Table 4.5; p  0.05: FRD  0.57. The pathways were generated from KEGG, a complete
computer representation of the cell, the organism, and the biosphere, which will enable
computational prediction of higher-level complexity of cellular processes and organism
behaviors from genomic and molecular information. KEGG is a recognized
bioinformatics data base and is part of the research projects of the Kanehisa Laboratories
in the Bioinformatics Center of Kyoto University and the Human Genome Center of the
University of Tokyo [81, 82]
The genes within the pathways were then explored for significance between the
cases and controls. The pathway report files included gene specific results for genes in
the pathways and a pathway p-value less than 0.10 per the method of Barry et al [74].
The analysis identified differentially expressed genes associated with the pathways and
are reported in Table 4.6  FDR 0.57. The table is labeled with the associated pathway
and includes the gene name and symbol, the case average of expression, the control
average of expression, permutation p value, false discovery rate (q), and the Affymetric
gene probe ID. A positive value of the test statistic indicates expression of the gene tends
to be higher in controls than cases and is denoted in blue; conversely, a negative value of
the test statistic indicated expression of the gene tended to be higher in cases than
controls and is denoted in red. A gene summary statement is also given and was retrieved
from Entrez Gene; a database designed to give detailed gene information and is linked
with relevant databases for additional reference [83]. This analysis provides a list of
genes of significant interest for function and their association with the phenotype and
became genes of high interest in the genotype analysis. It is noted that many of the genes
are involved in multiple pathways that are significant within this analysis. Additionally,
the same gene may be reported multiple times within a pathway due to gene splicing and
expressed as differences in the gene isoforms, which may be verified with the Affymetric
probe ID.
The 12 pathways of significance are involved in amino acid metabolism,
metabolism of cofactors and vitamins, biosynthesis of secondary metabolites, folding,
sorting, and degradation of proteins, translation, and DNA replication and repair. Within
these pathways, the global gene analysis found significant differences in gene expression
between the cases and controls; however, each of these genes has a high false discovery
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Table 4.5 12 Affymetrix-Defined Pathways of Significance.
Defined Pathway

Test Stat

Perm. p.

False
Discovery (q)

Methionine Metabolism

50.67365

0.0015

0.3495

Selenoamino Acid Metabolism

55.48675

0.0051

0.5736

Phenylalanine, Typrosine and
Tryptophan biosynthesis

39.28965

0.014

0.5736

Alkaloid Biosynthesis

24.16919

0.014

0.5736

Aminoacyl-tRNA Biosynthesis

86.91439

0.0177

0.5736

Nicotinate and Nicotinamide
Metabolism

70.03519

0.0263

0.5736

One Carbon Pool by Folate

58.43735

0.0314

0.5736

Tetracycline Biosynthesis

19.23147

0.0336

0.5736

Type II Secretion System

7.301847

0.0413

0.5736

Histidine Metabolism

111.7057

0.0415

0.5736

DNA Polymerase

28.78765

0.0452

0.5736

Phenylalanine Metabolism

105.2655

0.0478

0.5736
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Table 4.6 Significant Genes Associated with Designated Pathways. Red denotes a
higher gene expression in cases, while blue denotes higher gene expression in controls.
Gene Name
(Gene Symbol)
MARS
Methionine-tRNA
synthetase
Location 12q13.2

Case
Average

2098.546

Control
Average

2500.1472

Perm P

0.0077

q

0.70

Probe-set ID

213671_s_at

Significant
Pathways
Methionine
Metabolism
Selenoamino acid
Metabolism
Aminoacyl-tRNA
biosymthesis

Gene Summary: Aminoacyl-tRNA synthetases are a class of enzymes that charge tRNAs with their
cognate amino acids. The protein encoded by this gene belongs to the class I family of tRNA
synthetases.
TRDMT1
tRNA aspartic acid
methyl-transferase 1
Location 10p15.1

451.7462

371.95833

0.01

0.70

206308_at

Methionine
Metabolism

Gene Summary: CpG methylation is an epigenetic modification that is important for embryonic
development, imprinting, and X-chromosome inactivation. This gene encodes a protein with similarity
to DNA methyltransferases, but this protein does not display methyltransferase activity. The protein
strongly binds DNA, suggesting that it may mark specific sequences in the genome. Alternative splicing
results in multiple transcript variants encoding different isoforms.
MARS
Methionine-tRNA
synthetase
Location 12q13.2

202.5

274.73889

0.02

0.71

213672_at

Methionine
Metabolism
Selenoamino acid
Metabolism
Aminoacyl-tRNA
biosymthesis

243529_at

Methionine
MetabolisSelenamin
o acid Metabolism
Aminoacyl-tRNA
iosynthesis

Gene Summary: Previously described
MARS2
methionine-tRNA
synthetase 2
(mitochondrial)
Location 2q33

182.4846

239.97222

0.023

0.71

Gene Summary: Aminoacyl-tRNA synthetases are a class of enzymes that charge tRNAs with their
cognate amino acids. The protein encoded by this gene belongs to the class I family of tRNA
synthetases
MAT2B methionine
adenosylransferase
II, beta Location
5q34-q35.1

21324.31

17708.381

0.027

0.71

217993_s_at

Methionine
Metabolism
Selenoamino acid
Metabolism

Gene Summary: The protein encoded by this gene belongs to the methionine adenosyltransferase
(MAT) family. MAT catalyzes the biosynthesis of S-adenosylmethionine from methionine and ATP.
This protein is the regulatory beta subunit of MAT. Alternative splicing occurs at this locus and two
transcript variants encoding distinct isoforms have been identified.
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Table 4.6 Continued.
Gene Name
(Gene Symbol)
MARS
Methionine-tRNA
synthetase Location
12q13.2

Case
Average

1483.392

Control
Average

1741.5194

Perm P

0.037

q

0.72

Probe-set ID

201475_x_at

Significant
Pathways
Methionine
Metabolism
Aminoacyl-tRNA
biosynthesis

Gene Summary: Previously described.
MTR 5methyltetrahydrofol
ate- homocysteine
methyltransferase
Location 1q43

11136.008

1417.133

0.0374

0.727

203774_at

Methionine
Metabolism
One carbon pool by
folate

Gene Summary: MTR encodes the enzyme 5-methyltetrahydrofolate-homocysteine methyltransferase.
This enzyme, also known as cobalamin-dependent methionine synthase, catalyzes the final step in
methionine biosynthesis. Mutations in MTR have been identified as the underlying cause of
methylcobalamin deficiency complementation group G.
DNMT3A
DNA (cytosine-5-)methyltransferase 3
alpha Location 2p23

431.8462

494.2083

0.0416

0.728

244428_at

Methionine
Metabolism

Gene Summary: CpG methylation is an epigenetic modification that is important for embryonic
development, imprinting, and X-chromosome inactivation. Studies in mice have demonstrated that
DNA methylation is required for mammalian development. This gene encodes a DNA
methyltransferase that is thought to function in de novo methylation, rather than maintenance
methylation. The protein localizes to the cytoplasm and nucleus and its expression is developmentally
regulated. Alternative splicing results in multiple transcript variants encoding different isoforms.
PAPSS2 3'phosphoadenosine
5'-phosphosulfate
synthase 2 Location
10q23-q24

139.1923

91.25

0.016

0.704

203059_s_at

Selenoamino acid
Metabolism

PAPSS2 3'phosphoadenosine
5'-phosphosulfate
synthase 2 Location
10q23-q24

535.6385

469.7139

0.0262

0.717

203060_s_at

Selenoamino acid
Metabolism

Gene Summary: Sulfation is a common modification of endogenous (lipids, proteins, and
carbohydrates) and exogenous (xenobiotics and drugs) compounds. In mammals, the sulfate source is
3'-phosphoadenosine 5'-phosphosulfate (PAPS), created from ATP and inorganic sulfate. Two different
tissue isoforms encoded by different genes synthesize PAPS. This gene encodes one of the two PAPS
synthetases.
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Table 4.6 Continued.
Significant
Pathways

Gene Name
(Gene Symbol)

Case
Average

Control
Average

Perm P

q

Probe-set ID

MARS
Methionine-tRNA
synthetase Location
12q13.2

1483.392

1741.5194

0.037

0.72

201475_x_at

Selenoamino acid
Metabolism

212048_s_at

Phenylalanine,
tyrosine tryptophan
biosynthesis
Aminoacyl-tRNA
biosynthesis

Gene Summary: Previously described
YARS
tyrosyl-tRNA
synthetase Location
1p35.1

1755.892

2400.817

0.0029

0.69

Gene Summary: Aminoacyl-tRNA synthetases catalyze the aminoacylation of tRNA by their cognate
amino acid. Because of their central role in linking amino acids with nucleotide triplets contained in
tRNAs, aminoacyl-tRNA synthetases are thought to be among the first proteins that appeared in
evolution. Tyrosyl-tRNA synthetase belongs to the class I tRNA synthetase family. Cytokine activities
have also been observed for the human tyrosyl-tRNA synthetase, after it is split into two parts, an Nterminal fragment that harbors the catalytic site and a C-terminal fragment found only in the
mammalian enzyme. The N-terminal fragment is an interleukin-8-like cytokine, whereas the released
C-terminal fragment is an EMAP II-like cytokine.
FARS2
phenylalaninetRNA synthetase 2
(mitochondrial)
Location 6p25.1

569.8

697.2167

0.0197

0.70

204282_s_at

Phenylalanine,
tyrosine
tryptophan
biosynthesis
Aminoacyl-tRNA
biosynthesis

Gene Summary: Aminoacyl-tRNA synthetases are a class of enzymes that charge tRNAs with their
cognate amino acids. This gene encodes a phenylalanine-tRNA synthetase (PheRS) localized to the
mitochondrion which consists of a single polypeptide chain, unlike the (alpha-beta)2 structure of the
prokaryotic and eukaryotic cytoplasmic forms of PheRS. Structure analysis and catalytic properties
indicate mitochondrial PheRSs may constitute a class of PheRS distinct from the enzymes found in
prokaryotes and in the eukaryotic cytoplasm.
ENO2
enolase 2 (gamma,
neuronal)

215.7615

296.916

0.0199

0.70

201313_at

Phenylalanine,
tyrosine
tryptophan
biosynthesis

Gene Summary: This gene encodes one of the three enolase isoenzymes found in mammals. This
isoenzyme, a homodimer, is found in mature neurons and cells of neuronal origin. A switch from alpha
enolase to gamma enolase occurs in neural tissue during development in rats and primates.
DDC dopa
decarboxylase
(aromatic L-amino
acid decarboxylase)
Location 7p11

63.95385

28.15833

0.0067

46

0.69

214347_s_at

Alkaloid
biosynthesis
Histidine
Metabolism
Phenylalanine
Metabolism

Table 4.6 Continued.
Gene Name
(Gene Symbol)
MARS
Methionine-tRNA
synthetase
Location 12q13.2

Case
Average

2098.546

Control
Average

2500.1472

Perm P

0.0077

q

0.70

Probe-set ID

213671_s_at

Significant
Pathways
Methionine
Metabolism
Selenoamino acid
Metabolism
Aminoacyl-tRNA
biosymthesis

Gene Summary: Aminoacyl-tRNA synthetases are a class of enzymes that charge tRNAs with their
cognate amino acids. The protein encoded by this gene belongs to the class I family of tRNA
synthetases.
TRDMT1
tRNA aspartic acid
methyl-transferase 1
Location 10p15.1

451.7462

371.95833

0.01

0.70

206308_at

Methionine
Metabolism

Gene Summary: CpG methylation is an epigenetic modification that is important for embryonic
development, imprinting, and X-chromosome inactivation. This gene encodes a protein with similarity
to DNA methyltransferases, but this protein does not display methyltransferase activity. The protein
strongly binds DNA, suggesting that it may mark specific sequences in the genome. Alternative splicing
results in multiple transcript variants encoding different isoforms.
MARS
Methionine-tRNA
synthetase
Location 12q13.2

202.5

274.73889

0.02

0.71

213672_at

Methionine
Metabolism
Selenoamino acid
Metabolism
Aminoacyl-tRNA
biosymthesis

243529_at

Methionine
MetabolisSelenamin
o acid Metabolism
Aminoacyl-tRNA
iosynthesis

Gene Summary: Previously described
MARS2
methionine-tRNA
synthetase 2
(mitochondrial)
Location 2q33

182.4846

239.97222

0.023

0.71

Gene Summary: Aminoacyl-tRNA synthetases are a class of enzymes that charge tRNAs with their
cognate amino acids. The protein encoded by this gene belongs to the class I family of tRNA
synthetases.
MAT2B
methionine
adenosylransferase
II, beta Location
5q34-q35.1

21324.31

17708.381

0.027

0.71

217993_s_at

Methionine
Metabolism
Selenoamino acid
Metabolism

Gene Summary: The protein encoded by this gene belongs to the methionine adenosyltransferase
(MAT) family. MAT catalyzes the biosynthesis of S-adenosylmethionine from methionine and ATP.
This protein is the regulatory beta subunit of MAT. Alternative splicing occurs at this locus and two
transcript variants encoding distinct isoforms have been identified.
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Table 4.6 Continued.
Gene Name
(Gene Symbol)
MARS
Methionine-tRNA
synthetase Location
12q13.2

Case
Average

1483.392

Control
Average

1741.5194

Perm P

0.037

q

0.72

Probe-set ID

201475_x_at

Significant
Pathways
Methionine
Metabolism
Aminoacyl-tRNA
biosynthesis

Gene Summary: Previously described
MTR 5methyltetrahydrofol
ate- homocysteine
methyltransferase
Location 1q43

11136.008

1417.133

0.0374

0.727

203774_at

Methionine
Metabolism
One carbon pool by
folate

Gene Summary: MTR encodes the enzyme 5-methyltetrahydrofolate-homocysteine methyltransferase.
This enzyme, also known as cobalamin-dependent methionine synthase, catalyzes the final step in
methionine biosynthesis. Mutations in MTR have been identified as the underlying cause of
methylcobalamin deficiency complementation group G.
DNMT3A
DNA (cytosine-5-)methyltransferase 3
alpha Location 2p23

431.8462

494.2083

0.0416

0.728

244428_at

Methionine
Metabolism

Gene Summary: CpG methylation is an epigenetic modification that is important for embryonic
development, imprinting, and X-chromosome inactivation. Studies in mice have demonstrated that
DNA methylation is required for mammalian development. This gene encodes a DNA
methyltransferase that is thought to function in de novo methylation, rather than maintenance
methylation. The protein localizes to the cytoplasm and nucleus and its expression is developmentally
regulated. Alternative splicing results in multiple transcript variants encoding different isoforms.
PAPSS2 3'phosphoadenosine
5'-phosphosulfate
synthase 2 Location
10q23-q24

139.1923

91.25

PAPSS2 3'phosphoadenosine
5'-phosphosulfate
synthase 2 Location
10q23-q24

535.6385

469.7139

0.0168
0.704

0.0262

0.717

203059_s_at

Selenoamino acid
Metabolism

203060_s_at

Selenoamino acid
Metabolism

Gene Summary: Sulfation is a common modification of endogenous (lipids, proteins, and
carbohydrates) and exogenous (xenobiotics and drugs) compounds. In mammals, the sulfate source is
3'-phosphoadenosine 5'-phosphosulfate (PAPS), created from ATP and inorganic sulfate. Two different
tissue isoforms encoded by different genes synthesize PAPS. This gene encodes one of the two PAPS
synthetases.
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Table 4.6 Continued.
Gene Name
(Gene Symbol)
TYR
tyrosinase
(oculocutaneous
albinism IA)
Location 11q14q21
AARS
alanyl-tRNA
synthetase Location
16q22

Significant
Pathways

Case
Average

Control
Average

Perm P

q

Probe-set ID

159.9538

109.6667

0.0133

0.70

206630_at

Alkaloid
biosynthesis

1105.031

1357.4944

0.0039

0.69

201000_at

Aminoacyl-tRNA
biosynthesis

Gene Summary: tRNA synthases are the enzymes that interpret the RNA code and attach specific
aminoacids to the tRNAs that contain the cognate trinucleotide anticodons. They consist of a catalytic
udomain which interacts with the amino acid acceptor-T psi C helix of the tRNA, and a second domain
which interacts with the rest of the tRNA structure.
LARS
l lecyl-tRNA
synthetase Location
5q32

2189.269

2854.6

0.0084

0.70

217810_x_at

Aminoacyl-tRNA
biosynthesis

Gene Summary: This gene encodes a cytosolic leucine-tRNA synthetase, a member of the class I
aminoacyl-tRNA synthetase family. The encoded enzyme catalyzes the ATP-dependent ligation of Lleucine to tRNA(Leu). It is found in the cytoplasm as part of a multisynthetase complex and interacts
with the arginine tRNA synthetase through its C-terminal domain.
LARS2
leucyl-tRNA
synthetase 2,
mitochondrial
Location 3p21.3

260.8538

297.0306

0.0492

0.73

34764_at

Aminoacyl-tRNA
biosynthesis

Gene Summary: This gene encodes a class 1 aminoacyl-tRNA synthetase, mitochondrial leucyltRNA synthetase. Each of the twenty aminoacyl-tRNA synthetases catalyzes the aminoacylation of a
specific tRNA or tRNA isoaccepting family with the cognate amino acid.
HARS
histidyl-tRNA
synthetase Location
5q31.

1129.131

1352.417

0.0554

0.74

202042_at

Aminoacyl-tRNA
biosynthesis
Histidine
Metabolism

Gene Summary: Aminoacyl-tRNA synthetases are a class of enzymes that charge tRNAs with their
cognate amino acids. The protein encoded by this gene is a cytoplasmic enzyme which belongs to the
class II family of aminoacyl-tRNA synthetases. The enzyme is responsible for the synthesis of
histidyl-transfer RNA, which is essential for the incorporation of histidine into proteins.
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Table 4.6 Continued.
Gene Name
(Gene Symbol)

Case
Average

Control
Average

Perm P

q

Probe-set ID

Significant
Pathways

NMNAT2
Nicotinate and
nicotinamide
155.7385
97.59167
0.001
0.67
1552712_a_at nicotinamide
nucleotide
metabolism
adenylyltransferase
2 Location 1q25
Gene Summary: This gene product belongs to the nicotinamide mononucleotide adenylyltransferase
(NMNAT) enzyme family, members of which catalyze an essential step in NAD (NADP) biosynthetic
pathway.
NT5C3 5'Nicotinate and
nucleotidase,
9632.208
6214.1278
0.032
0.72
223298_s_at
nicotinamide
cytosolic III
metabolism
Location 7p14.3
Gene Summary: Pyrimidine 5-prime-nucleotidase (P5N; EC 3.1.3.5), also called uridine 5-prime
monophosphate hydrolase (UMPH), catalyzes the dephosphorylation of the pyrimidine 5-prime
monophosphates UMP and CMP to the corresponding nucleosides
PBEF1
pre-B-cell colony
enhancing factor 1
Nicotinate and
pre-B cell
42190.62
34318.536
0.043
0.7
217739_s_at
nicotinamide
enhancing factor 1
metabolism
pseudogene
Location 7q22.2 ///
10p11.21
Gene Summary: This gene encodes a protein that catalyzes the condensation of nicotinamide with 5phosphoribosyl-1-pyrophosphate to yield nicotinamide mononucleotide, one step in the biosynthesis of
nicotinamide adenine dinucleotide. The protein is an adipokine that is localized to the bloodstream and
has various functions, including the promotion of vascular smooth muscle cell maturation and
inhibition of neutrophil apoptosis. It also activates insulin receptor and has insulin-mimetic effects,
lowering blood glucose and improving insulin sensitivity. The protein is highly expressed in visceral fat
and serum levels of the protein correlate with obesity. This gene has a pseudogene on chromosome 10.
NMNAT2
nicotinamide
41.99231
20.952778
nucleotide
adenylyltransferase
2 Location 1q25
Gene Summary: Previously described

0.046

0.73

209755_at

Nicotinate and
nicotinamide
metabolism

NT5E 5'Nicotinate and
nucleotidase, ecto
67.71538
99.030556
0.049
0.73
227486_at
nicotinamide
(CD73) Location
metabolism
6q14-q21
Gene Summary: Ecto-5-prime-nucleotidase (5-prime-ribonucleotide phosphohydrolase; EC 3.1.3.5)
catalyzes the conversion at neutral pH of purine 5-prime mononucleotides to nucleosides, the preferred
substrate being AMP. The enzyme consists of a dimer of 2 identical 70-kD subunits bound by a
glycosyl phosphatidyl inositol linkage to the external face of the plasma membrane. The enzyme is used
as a marker of lymphocyte differentiation. Consequently, a deficiency of NT5 occurs in a variety of
immunodeficiency diseases
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Table 4.6 Continued.
Gene Name
(Gene Symbol)

Case
Average

Control
Average

Perm P

q

Probe-set ID

Significant
Pathways

TYMS Thymidylate
synthetase Location
18p11.32

128.5154

187.9

0.006

0.69

243016_at

One carbon pool by
folate

Gene Summary: Thymidylate synthase (TYMS, or TS; EC 2.1.1.45) uses the 5,10methylenetetrahydrofolate (methylene-THF) as a cofactor to maintain the dTMP (thymidine-5-prime
monophosphate) pool critical for DNA replication and repair. The enzyme has been of interest as a
target for cancer chemotherapeutic agents. It is considered to be the primary site of action for 5fluorouracil, 5-fluoro-2-prime-deoxyuridine, and some folate analogs.
DHFR///LOC64350
9 dihydrofolate
reductase /// similar
One carbon pool by
240.7385
311.76389
0.008
0.70
48808_at
to Dihydrofolate
folate
reductase Location
5q11.2-q13.2 ///
18q11.2
Gene Summary: Dihydrofolate reductase converts dihydrofolate into tetrahydrofolate, a methyl group
shuttle required for the de novo synthesis of purines, thymidylic acid, and certain amino acids. While
the functional dihydrofolate reductase gene has been mapped to chromosome 5, multiple intronless
processed pseudogenes or dihydrofolate reductase-like genes have been identified on separate
chromosomes
SHMT1
serine
One carbon pool by
80.466667
0.338
0.72
217304_at
hydroxymethyltransf 119.7846
folate
erase 1 (soluble)
Location 17p11.2
Gene Summary: This gene encodes the cellular form of serine hydroxymethyltransferase, a pyridoxal
phosphate-containing enzyme that catalyzes the reversible conversion of serine and tetrahydrofolate to
glycine and 5,10-methylene tetrahydrofolate. This reaction provides one carbon units for synthesis of
methionine, thymidylate, and purines in the cytoplasm.
TYMS
thymidylate
31.77692
21.111111
synthetase Location
18p11.32
Gene Summary: Previously described

0.044

0.73

217684_at

One carbon pool by
folate

ACACA
Tetracycline
acetyl-Coenzyme A 198.8846
352.24167
0.0008
0.67
212186_at
biosynthesis
carboxylase alpha
Location 17q21
Gene Summary: Acetyl-CoA carboxylase (ACC) is a complex multifunctional enzyme system. ACC
is a biotin-containing enzyme which catalyzes the carboxylation of acetyl-CoA to malonyl-CoA, the
rate-limiting step in fatty acid synthesis. There are two ACC forms, alpha and beta, encoded by two
different genes. ACC-alpha is highly enriched in lipogenic tissues. The enzyme is under long term
control at the transcriptional and translational levels and under short term regulation by the
phosphorylation/dephosphorylation of targeted serine residues and by allosteric transformation by
citrate or palmitoyl-CoA.
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Table 4.6 Continued.
Gene Name
(Gene Symbol)

Case
Average

Control
Average

Perm P

q

Probe-set ID

ACACB
acetyl-Coenzyme A
carboxylase beta
Location 12q24.11

212.2308

294.34722

0.033

0.72

49452_at

Significant
Pathways
Tetracycline
biosynthesis

Gene Summary: Acetyl-CoA carboxylase (ACC) is a complex multifunctional enzyme system. ACC
is a biotin-containing enzyme which catalyzes the carboxylation of acetyl-CoA to malonyl-CoA, the
rate-limiting step in fatty acid synthesis. ACC-beta is thought to control fatty acid oxidation by means
of the ability of malonyl-CoA to inhibit carnitine-palmitoyl-CoA transferase I, the rate-limiting step in
fatty acid uptake and oxidation by mitochondria. ACC-beta may be involved in the regulation of fatty
acid oxidation, rather than fatty acid biosynthesis.
DCTD
dCMP deaminase
Location 4q35.1

785.7692

943.88889

0.011

0.70

201572_x_at

Type II section
system

DCTD

960.6692

1117.6056

0.105

0.78

210137_s_at

Type II section
system

Gene Summary: The protein encoded by this gene catalyzes the deamination of dCMP to dUMP, the
nucleotide substrate for thymidylate synthase. The encoded protein is allosterically activated by dCTP
and inhibited by dTTP, and is found as a homohexamer. This protein uses zinc as a cofactor for its
activity.
ABP1

61.82308

27.313889

0.005

0.69

242452_at

ABP1

76.28462

117.71667

0.007

0.70

229156_s_at

ABP1

940.4462

1124.4139

0.026

0.71

236401_at

ABP1
Amiloride binding
protein 1 (amine
oxidase (coppercontaining) Location
7q34-q36

2142.508

2590.5944

0.033

0.72

236583_at

Histidine
Metabolism
Phenylalanine
Metabolism
Histidine
Metabolism
Phenylalanine
Metabolism
Histidine
Metabolism
Phenylalanine
Metabolism
Histidine
Metabolism
Phenylalanine
Metabolism

Gene Summary: This gene encodes a membrane glycoprotein that is expressed in many epitheliumrich and/or hematopoietic tissues and oxidatively deaminates putrescine and histamine. The protein may
play a role in controlling the level of histamine and/or putrescine in these tissues. It also binds to and is
inhibited by amiloride, a diuretic that acts by closing epithelial sodium ion channels.
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Table 4.6 Continued.
Gene Name
(Gene Symbol)

Case
Average

Control
Average

Perm P

q

Probe-set ID

MAOA

157.7385

72.35

0.0121

0.70

A 212741_at

MAOA monoamine
oxidase Location
Xp11.3

143.4769

104.04167

0.021

0.70

234534_at

Significant
Pathways
Histidine
Metabolism
Phenylalanine
Metabolism
Histidine
Metabolism
Phenylalanine
Metabolism

Gene Summary: This gene encodes monoamine oxidase A, an enzyme that degrades amine
neurotransmitters, such as dopamine, norepinephrine, and serotonin. The protein localizes to the
mitochondrial outer membrane. The gene is adjacent to a related gene on the opposite strand of
chromosome X. Mutation in this gene results in monoamine oxidase deficiency.
POLB Polymerase
(DNA directed),
beta Location
8p11.2

18.22308

35.7

0.005

0.69

234907_x_at

DNA Polymerase

Gene Summary: In eukaryotic cells, DNA polymerase beta (POLB) performs base excision repair
(BER) required for DNA maintenance, replication, recombination, and drug resistance.
POLS
Polymerase (DNA
directed) Sigma
Location 5p15

1525.169

1910.8167

0.005

0.69

202466_at

DNA Polymerase

Gene Summary: The protein encoded by this gene is a DNA polymerase that is likely involved in
DNA repair. In addition, the encoded protein may be required for sister chromatid adhesion.
POLG
Polymerase (DNA
directed), gamma
Location 15q25

567.2154

754.58056

0.006

0.69

203366_at

DNA Polymerase

PRDX2
Phenylalanine
Metabolism
peroxiredoxin 2
Location 19p13

203.8846

155.89167

0.039

0.72

201006_at

Phenylalanine
Metabolism

Gene Summary: This gene encodes a member of the peroxiredoxin family of antioxidant enzymes,
which reduce hydrogen peroxide and alkyl hydroperoxides. The encoded protein may play an
antioxidant protective role in cells, and may contribute to the antiviral activity of CD8(+) T-cells. This
protein may have a proliferative effect and play a role in cancer development or progression. The
crystal structure of this protein has been resolved to 2.7 angstroms.
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rate, giving the expected proportion of false positives among the declared significant
results and accounts for the testing of thousands of hypotheses simultaneously [75].
Primary Aim Two
Assess whether genotypes differ between two groups of radiated pediatric
Hodgkin lymphoma survivors with and without the development of secondary
breast cancer.
A total of 397,877 SNPs passed the variation requirement for detailed statistical
analysis. At a p-value threshold of 0.001, the robust FDR estimate is 1, indicating that
most or all SNPs are false discoveries. Due to the large number of SNP’s and false
discovery rate of 1, the SNP’s with a chi square p value < 0.001 were transformed into a
minuslog P which is 10 based –log of the chi-square p values and described in Appendix
E.
To determine the genes associated with the SNP’s of interest, a Geneset
enrichment p-value file was created and consisted of 13, 090 genes, of which 574 had a
p-vaule of 0.05 and false discovery rate of 1. This file gave the gene name,
chromosome number, the start and end location of the gene, gamma test statics,
permutation p value, and FDR Value. This file provided additional location of the gene
chromosome and relationship to SNP.
To visualize the results, a plot was created and corresponds to the –log10 p-value
of the SNP which corresponds to having a chi-square p-value < 0.001. Each of the SNP’s
having a –log10 p > than 3 (p < 0.001) is distinguished on the plot with a red dot and
displayed for each chromosome in Figures 4.1-4.23. These figures mark clusters of
SNP’s and their corresponding location and become those of highest interest. The
chromosomes which displayed the highest number of significant SNP differences
between cases and controls were chromosomes 5, 10, and 11.
Chromosome 5 displays a significant SNP_1907286 (-log 10 p= 4.8) at position
31786818 and is associated with the PDZD2 gene although not statically significant
(p=0.49; FDR1). Chromosome 10 had the largest number of SNP’s differentially
expressed with a region of 6.1 kilobases containing 11 differentially expressed SNPs
between the cases and controls. Two highly significant SNP’s within this region are
SNP_A-2181577 (-log 10 p=3.97) and SNP_A-2006464 (-log 10 p=3.97) at position
127481155 and 127485797 and statistically associated with the UROS gene (p=.001;
FDR 1). The most significant SNP within the region of chromosome 10 was SNP_A1842005 (-log 10 p= 3.98) at position 127508528 and statistically associated with the
BCCIP gene (p=.001; FDR 1). Within this polymorphic region there were two other
genes that were significant in the analysis, MMP21 (p=.001: FDR 1) and DHX32
(p=.001: FDR 1). The analysis found the most significant SNPs, SNP_A-2294376 (-log
10 p=5.1) and SNP_A-2209464 (-log 10 p=5.2), to be located on chromosome 11 at
position 119148037 and 119149661 and associated with the genes TRIM29 (p=0.845)
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Figure 4.1 Peak p-Values for Chromosome 1.

Figure 4.2 Peak p-Values for Chromosome 2.
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Figure 4.3 Peak p-Values for Chromosome 3.

Figure 4.4 Peak p-Values for Chromosome 4.
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Figure 4.5 Peak p-Values for Chromosome 5.

Figure 4.6 Peak p-Values for Chromosome 6.
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Figure 4.7 Peak p-Values for Chromosome 7.

Figure 4.8 Peak p-Values for Chromosome 8.
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Figure 4.9 Peak p-Values for Chromosome 9.

Figure 4.10 Peak p-Values for Chromosome 10.
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Figure 4.11 Peak p-Values for Chromosome 11.

Figure 4.12 Peak p-Values for Chromosome 12
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Figure 4.13 Peak p-Values for Chromosome 13.

Figure 4.14 Peak p-Values for Chromosome 14.
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Figure 4.15 Peak p-Values for Chromosome 15.

Figure 4.16 Peak p-Values for Chromosome 16.
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Figure 4.17 Peak p-Values for Chromosome 17.

Figure 4.18 Peak p-Values for Chromosome 18.
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Figure 4.19 Peak p-Values for Chromosome 19.

Figure 4.20 Peak p-Values for Chromosome 20.
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Figure 4.21 Peak p-Values for Chromosome 21.

Figure 4.22 Peak p-Values for Chromosome 22.
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Figure 4.23 Peak p-Values for Chromosome 23. (X chromosome)
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and PVRL (p=0.142). However, these genes were not statistically associated with the
SNP in the Geneset enrichment file.
Primary Aim Three
Identify candidate copy number variants that may be associated with the risk
of secondary breast cancer.
This analysis identified 130 in silico amplifications or deletions. Multiple cases
and controls had common regions of amplification (gain) or deletion (loss) in sections of
chromosomes 2, 14, and 15. In silico copy number variants were detected in 2q 37.3 for 5
subjects, 14q11.2 for 8 subjects, and 15q11.2 for 24 subjects.
There is some evidence that case-control status is associated with in silico copy
number of a section of 14q11.2 and 15q11.2. Within 14q11.2, gain was observed in 3 of
13 (23%) cases, 3 of 36 controls (8%), and 1 case had a deletion (p=0.069). Within
15q11.2, gain was observed in 11 of 36 controls (30.5%) and no cases (0%), diploid
status was inferred for 16 of 36 controls (44%) and 9 of 13 cases (69%) and loss was
inferred for 4 of 13 cases (30.7%) and 9 of 36 controls (25%) (p=0.067). The copy
number prevalence over the region of 14q11.2 is illustrated in Figure 4.24 and the
correlated genes expression plots for chromosome 14 are given in Figure 4.25.
The genes associated with copy number variation 14q11.2, OR4N4 and OR4Q3
are olfactory genes known to be the largest gene family within the genome and known to
regions of variability and have no known association with the study phenotype.
The copy number prevalence over the region of 15q11.2 is depicted in Figure
4.26. Chromosome 15 had 19 Affymetric gene probe sets found to be within the region
of copy number variation between those with a deletion, gain, or diploid within 15q11.2.
The Affymetric gene probe set and corresponding gene are described in Table 4.7. From
these probe sets, 19 expression plots were generated; however, only the genes with
specific interest are depicted in Figures 4.27-32 and include PAK2, CYFIP1, NIPA1,
NIPA2, TUBGCP5, and BCL8.
The family history of breast cancer was then analyzed with consideration of copy
number variation. The analysis found no association with gain or no change within the
region; however, there was an association (p=0.0392) as depicted in Table 4.8 with
deletion within the 15q11.2 region and having a first degree relative with breast cancer.
No association was found with second degree relative and copy number deletion.
Summary of Results
Aim one described the global gene expression between the cases and controls
with defined Affymetric pathways and genes that were significantly differentially
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Figure 4.24 Prevalence of Inferred Copy Number Variation among Cases and Controls
within 14q11.2.
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Figure 4.25 Gene Expression Correlated with Copy Number Variation at 14q11.2. (X –
Case; O – Control)
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Figure 4.26 Prevalence of Inferred Copy Number Variation among Cases and Controls
within 15q11.2. (X – Case; O – Control)
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Table 4.7 Genes Associated with Copy Number Variation at 15q11.2.
Probe Set

Gene Symbol / Name

208923_at

CYFIP1: Cytoplasmic FMR1 Interacting protein

235083_at
236283_x_at

FLJ38359: hypothetical protein

239899_at
1552696_at

1556739_at
1560683_at
1560684_x_at
1564855_at
1564856_at
1569013_at
212129_at
212133_at
214876_s_at
216193_at
225752_at
226077_at
227967_at
234912_at

PAK2: CDKNIA activated kinase 2
RNF145: Ring finger protein 145
NIPA1: non imprinted in Prader Will Angleman Snydrome 1
FLJ35785: hypothetical protein
LOC653125: Similar to glolgi autoantigen
LOC653720: Golgi Subfamily a, 8A
BCL8: B-cell CLL/lymphoma
BCL8: B-cell CLL/lymphoma
LOC727924: hypothetical protein
LOC 727924: hypothetical protein
LOC 96610: hypothetical protein
NIPA2: non imprinted in Prader Will Angleman Snydrome 2
NIPA2: non imprinted in Prader Will Angleman Snydrome 2
TUBGCP5: Tubulin, gamma complex associated protein 5
LOC 440366: hect domain and RLD 2 pseudogene
NIPA1: non imprinted in Prader Will Angleman Snydrome 1
RNF 145: Ring finger protein 145
TUBGCP5: Tubulin, gamma complex associated protein 5
LOC 651964: hypothetical protein
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Figure 4.27 Correlation of CYFIP1 Gene Expression and Copy Number Variation. (X –
Case; O – Control)

72

Figure 4.28 Correlation of PAK2 Gene Expression and Copy Number Variation. (X –
Case; O – Control)

73

Figure 4.29 Correlation of NIPA1 Gene Expression and Copy Number Variation. (X –
Case; O – Control)
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Figure 4.30 Correlation of NIPA2 Gene Expression and Copy Number Variation. (X –
Case; O – Control)
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Figure 4.31 Correlation of BCL8 Gene Expression and Copy Number Variation. (X –
Case; O – Control)
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Figure 4.32 Correlation of TUBGCP5 Gene Expression and Copy Number Variation.
(X – Case; O – Control)
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Table 4.8 Association of First Degree Breast Cancer Family History and Deletion at
15q11.2. 95% Confidence.
Parameter

Estimate

Limits

Relative 1

9.499

1.092

135.406

0.0392

Relative 2

2.730

0.380

20.335

0.4154
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p-Value

expressed between the cases and controls. This provided pathways and genes of interest
in association with the phenotype of HL and breast cancer. The analysis found significant
differences between the cases and controls in genes involved in amino acid metabolism,
metabolism of cofactors and vitamins, biosynthesis of secondary metabolites, folding,
sorting, and degradation of proteins, translation, and DNA replication and repair.
Therefore, there are differences in the global gene expression between those with and
without secondary breast cancer.
Aim two explored the genotype variability between cases and controls and found
a large number of SNP variation and statistical differences between the genotype of those
with and without secondary breast cancer. The most significant SNP variability between
cases and controls was noted on chromosomes 5, 10, and 11. A region of genotype
variability on chromosome 10 is of great interest due to the significant association with
the BCCIP gene (p=.001) and the genes known interaction with BRCA2 and the
phenotype of breast cancer.
Lastly, the analysis of aim three screened for evidence of amplification or deletion
within the SNP array signal data to determine a set of candidate genes and region of
interest associated with case/control status. The analysis found inferred regions of
14q11.2 and 15q11.2 through copy number variation to have some association with
case/control status. An analysis of association of inferred copy number variation with the
expression of individual probe sets resulted in a list of candidate genes within these
regions. Region 14q11.2 found two genes within the region of interest with both being
from the large olfactory gene family and known to have significant variability. The
region of 15q11.2 found 19 candidate genes of interest most specifically genes found to
be associated with the phenotype of breast cancer and lymphoma and include PAK2,
CYFIP1, NIPA1, NIPA2, TUBGCP5, BCL8, and numerous hypothetical proteins.
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CHAPTER 5. DISCUSSION
Discussion of Findings
Chapter 5 presents a discussion of the demographic data and the primary aims.
The findings will be discussed in relation to the conceptual framework along with nursing
implications and recommendations.
Demographic Data
Cases and controls were well matched with no statistical differences in age at HL
diagnosis and time since diagnosis, maximum dose of mantel/mediastinal radiation, or
alkylating chemotherapy. Comparison of demographic data for age of menses,
menopause, and hormonal use found only the age of menopause (p=0.0191) to be
statistically different between the cases and controls. This difference is most likely due to
the fact that cases and controls were not matched for para-aortic and/or pelvic radiation.
For the controls who received pelvic radiation, early age of menopause with onset prior
to 31 years of age may be most protective against breast cancer [14]. The age at 1st
pregnancy and time of pregnancy after HL have been described as being associated with
secondary breast cancer [53]; however, these ages were not statistically different between
the cases and controls. Although not significant, the reproductive history did find that the
controls had fewer numbers of pregnancies and live births in comparison to the cases.
This may be related to the earlier menopause secondary to a higher incidence of pelvic
radiation or other factors that contributed to reproductive decisions. Lastly, the cases and
controls provided a self report of first and second degree family members with cancer.
Both the cases and controls reported a 45% incidence of cancer among first and second
degree relatives with breast being a common cancer among both first and second degree
relatives.
Breast cancer among the cases was diagnosed on average 36.5 ± 6.7 years of age,
with a range of 27.2-51 years, which is significantly younger than the general population
median diagnosis age of 61 years [12]. The time from radiation to the development of
breast cancer was on average 21.3 ± 5.8 years after radiation and is consistent with the
previously described range of 15 to 20 years [3, 5, 7]. The controls are approximately
25.4 ± 6.01 years (range 15.2-33.8 years) from HL diagnosis. This is important in that the
majority of controls have exceeded the passage of time and the period of highest relative
risk of secondary breast cancer after radiation exposure. However, there is significant
variability with a standard deviation ± 6.01 years, meaning that some controls remain at
an increased relative risk. The cases were also asked specifics regarding their breast
cancer histology and hormonal markers. Information for the cases and chart review
revealed no difference between the presentation of those with secondary breast cancer
and sporadic disease. While bilateral disease has been reported to occur more frequently
among HL survivors [3], only one case reported a bilateral occurrence.
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Age at menopause (p=0.0191) was the only significant variable with statistical
difference between the cases and controls. Overall, the demographic data found these
survivors of pediatric HL to be a very homogenous group except for the occurrence of
secondary cancer.
Primary Aim One
Aim one sought to determine the global gene expression differences between
cases and controls. The global gene expression found significant gene expression
differences in genes that are inter-related within 12 molecular pathways. These 12
pathways can be grouped into larger pathways of amino acid metabolism, metabolism of
cofactors and vitamins, biosynthesis of secondary metabolites, and genetic information
processing including folding, sorting and degradation, translation, and DNA
replication/repair. The 12 significant pathways are outlined in Table 5.1. Within these
pathways 43 genes and their isoforms were differently expressed between cases and
controls with test p-value and permutation p-values of significance. However, the false
discovery rate for each of the genes was .70 or greater indicating that 70% of the reported
results are expected to be false discoveries. Although the data declare a high false
discovery rate, the gene set is of interest in relation to the phenotype of secondary breast
cancer.
Pathways of Significance
Folate-Methionine Pathway. One carbon metabolism, DNA methylation, synthesis, and
repair have been long studied as mechanisms for the development of carcinogenesis. The
methionine and folate metabolizing pathways are integral for DNA synthesis and
methylation and are of interest with this study phenotype. During translation and
transcription, gene expression is associated with the patterns of modification of DNA
through the process of methylation. The process of methylation is not an alteration in the
nucleotide sequence, but results from an addition of a methyl group to the cytosinephopshoguanine (CpG) promoter region of the gene [84] . These CpG islands are located
in over half of all human genes [85]. Gene expression can be altered by DNA methylation
resulting in both hypomethylation and hypermethylation. DNA hypomethylation has been
correlated with cancer through activation of proto-oncogenes, reactivation of transposable
elements, and loss of imprinting [86]. Hypermethylation results in gene repression of
tumor suppressors, chromatin condensation, and loss of DNA repair [87]. Methylation
has been implicated as an early event in breast cancer, with the activation of oncogenes
and the suppression of tumor suppressors.
Many of the genes involved in DNA methylation and synthesis were statistically
significant in their differential expression between cases and controls as described and
depicted in Figure 5.1. The first described is thymidylate synthetase (TS OR TYMS)
which binds methylenetetrahydrofolate (5, 10-methylene THF) and serves as a
hydroxymethyl donor in the conversion of dUMP to dTMP which is critical in DNA
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Table 5.1 Grouping of Significant Pathways.
Pathway Function

Pathway

Amino Acid Metabolism

Methionine Metabolism
Histindine Metabolism
Phenylalanine, Tyrosine, and Tryptophan
Biosynthesis
Phenylalanine Metabolism

Metabolism of Other Amino Acids

Selenoamino Acid Metabolism

Metabolism of Cofactors and Vitamins
Biosynthesis of Secondary Metabolites

Nicotinate and Nicotinamide Metabolism
One Carbon Folate Pool
Alkaloid Biosynthesis I
Tetracycline Biosynthesis

General Information Processing
Folding, Sorting, and Degradation

Type II Secretion

Translation

Aminoacyl-tRNA biosynthesis

Replication and Repair

DNA Polymerase
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Up-regulated in
Controls in

Up-regulated in Cases
Comparison to

Up-regulated in
Controls in

Figure 5.1 DNA Syntheses and Methylation. Adapted with permission of Wiley-Liss,
Inc. a subsidiary of John Wiley & Sons, Inc. from Lissowska, et al. Genetic
polymorphisms in the one-carbon metabolism pathway and breast cancer risk: a
population-based case-control study and meta-analyses. Int. J. of Cancer. 2007. 120: p
2697 [122].
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synthesis and was expressed higher among the controls. Another gene, dCMP deaminase
(DCTD) within the Type II secretion system pathway catalyzes the deamination of dCMP
to DUMP a substrate for thymidylate syntase and was expressed higher among the
controls. Inter-related is the process of DNA methylation in which
methylenetetrahydrofolate reductase (MTHFR) catalyzes the reduction of 5, 10
methylenetetrahydrofolate (methylene THF) to 5-methyl THF, 5-methyl THF is the
circulating form of folate and carbon donor for the remethylation of homocysteine to
methionine. Therefore, MTHFR is important in homocysteine metabolism, methionine
synthesis and methylation reactions. Reduced gene activity may result in accumulation of
5, 10 methylene THF and reduced 5-methyl THF. Although not statistically significant,
controls were found to have a higher expression of MTHFR than the cases. From the
methionine, methionine adenosyltransferase (MAT2B) catalyzes the biosysnthesis of Sadenosylmethionine (SAM) and was expressed higher among the cases.
Two vitamin B dependent enzymes were expressed differently between cases and
controls. Methionine synthase (MTR) is a vitamin B-12 dependent enzyme and catalyzes
the methyl base from 5-methyl THF to homocysteine for the production of methionine
and tetrahydrofolate. MTR is also important in maintaining S-adenosylmethionine (SAM)
for DNA methylation and preventing increased homocysteine and was significantly
expressed higher among the controls. Vitamin B6 enzyme, serine
hydroxymethyltransferase (SHMT) was found to be expressed higher in the cases than
controls. SHMT is responsible for conversion of serine and THF to glycine and
methylene THF and is important in providing one-carbon units for purine, thymidylate,
and methionine synthesis. Lastly, within Figure 5.1 is dihydrofolate reductase (DHFR)
which was expressed higher among controls. This gene is within the one carbon folate
pathway and required for de novo synthesis of amino acids.
Lastly, two genes of importance within the methionine metabolism were tRNA
aspartic acid methyl-transferase (TRDMT1) expressed higher in the cases and DNA
methyltransferase 3 alpha (DMT3A) expressed higher in the controls. Both of the
these genes regulate CpG methylation. The DNMTs transfer a methyl group from SAM
to generate methylation and the silencing of genes [88]. DNMT3a is a de novo
methyltransferase and functions to methylate unmethylated DNA.
Dietary intake has been linked with DNA methylation and most specifically
deficiencies in folic acid, methionine, zinc, selenium have been implicated [89]. While
the nutritional data remains controversial, there is the link of 5-methylenetetrahydrofolate
as the precursor of the methyl group needed for methionine to SAM [90]. While adequate
nutrients are needed, excess of intake of folic acid, methionine, and selenium have been
known to disrupt DNA methylation [87]. There are many factors that are important in
maintenance of the folate-methionine pathway with gene expression being differently
expressed between the cases and controls.
t-RNA-Depedendent Amino Acid Biosynthesis. The aminoacyl-tRNAs are essential
substrates in the process of translation and protein synthesis. As ribosome moves along
the mRNA aligning the codons, aminoacylated-tRNA is brought into line for the transfer
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from the mRNA into the growing amino acid polypeptide chain. Each aminoacyl-tRNA
synthetase recognizes its specific amino acid. Therefore, the aminoacylated t-RNA is
essential in genetic coding and serves a major function as RNA editors. Most of the
aminoacyl-tRNAs can distinguish their corresponding amino acid; however, many can
not bringing in the importance of pre and post transfer editing [91]. Mutations within
aminoacylated t-RNA result in ambiguity of the genetic code and missense substitutions.
Among the cases and controls, the t-RNA depedendent amino acid biosynthesis
pathway was statistically significant. Eight aminoacyl-tRNA associated genes were
differentially expressed and all were significantly expressed higher among controls than
cases. These genes included: three isoforms of MARS which is a methionine tRNA
synthetase and MARS2 which is the tRNA synthetase responsible for mitochondrial
tRNA, YARS tyrosyl tRNA synthase FARS2 phenylalanine tRNA synthetase
mitochondrial, AARS alanyl tRNA synthase, LARS and LARS2 leucyl tRNA synthase,
and HARS histidyl tRNA synthase. It could be inferred that lower gene expression
among cases may be responsible for impaired protein synthesis.
Nicotinate and Nicotinamide Metabolism. The metabolism of nicotinate and nicotinamide
are pathways of interest due to their response to cellular stress for which four genes were
expressed higher among the cases than controls. Two isoforms of nicotinamide
nucleotide adenylyltransferase 2 (NMNAT2) a family of enzymes which catalyze an
important step in nicotinamide adenine dinucleotide (NAD) biosynthesis were
differentially expressed. Another gene pre-B-cell colony enhancing factor 1 (PBEF1) was
also expressed higher among the cases and is involved in the biosynthesis of NAD. The
biosynthesis of NAD is of interest within cases in that DNA damage is found to stimulate
NAD biosynthesis and recovery of damage occurs sooner with higher levels of NAD
[92].
DNA Polymerase. DNA polymerases are important in the repair of DNA after toxic
exposure and prevent mutagenic lesions within the DNA. Many DNA polymerases are
known and three were differently expressed higher among the controls than cases and
include Poly beta sigma and gamma. Poly beta supports DNA maintenance, replication,
and recombination through base excision repair. Poly beta has been found to be involved
in DNA repair of UV lesions allowing DNA to repair through translesion synthesis[93].
In tumor formation, an increased expression of Poly beta is consistent with synthesis of
genes needed for DNA repair in an attempt to detain the mutagenic lesion [ 94, 101].
Biosynthesis of Secondary Metabolites. Another gene of interest and associated with
breast cancer is Acetyl-CoA carboxylase  which was expressed higher among the
controls. This gene has been identified as being a partner of the breast cancer gene
BRCA1 and interacts with AAC  via the tandem of BRCT domains in BRCA1 [94].
Therefore, the higher expression among the controls may facilitate the interaction and
function of BRCA1. This gene has been found to be expressed in the liver, adipose, brain
and mammary gland during lactation. AAC  is highly expressed in breast carcinoma
[94].
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Global Gene Expression Summary
The study finds that there are differences in the global gene expression between
those with and without secondary breast cancer. The expression data defines 12
molecular pathways and 43 genes (p  0.05) differentially expressed between the cases
and controls within each of the pathways. Most specifically, the cases were found to have
lower expression in the folate-. methionine, t-RNA-Depedendent Amino Acid
Biosynthesis, Nicotinate and Nicotinamide Metabolism. Regardless of the direction of
change in gene expression, differences were found between the cases and controls and
occurred within key processes of amino acid metabolism, one-carbon metabolism, DNA
replication, and RNA translation.
These pathways of interest are very similar to those described by the consensus
coding sequences of human breast and colon cancer [95]. This study evaluated genetic
mutations of tumors, focusing on protein coding genes or consensus coding sequences.
This data generated a list of somatic mutations and candidate cancer genes. Each of these
genes was assigned a function based on molecular function or biochemical processes. For
breast cancer 18% of the genes were transcriptional regulators, of particular zinc finger
transcription factors. Additional pathways included cellular adhesion and motility, signal
transduction, transport, cellular metabolism, intracellular trafficking, and RNA
metabolism, and response to DNA damage stimulus [95]. Many of the described
pathways within the tumor from the consensus coding sequences were found from this
study of germline gene expression. Therefore, differential expression within these
pathways may be important in the transformation of the breast cancer phenotype in cases.
Primary Aim Two
Aim two determined the genotype differences between the cases and controls, and
found there to be SNP’s of statistical significance in allele frequency between the cases
and controls. As previously discussed, the most significant SNP’s with a chi-square pvalue < 0.001 were transformed, plotted, and highlighted according to the chromosome
location. A Geneset enrichment p-value file was created to determine the genes
associated with the SNP’s of interest and found 574 genes associated with the
corresponding SNP. SNP’s of greatest significance and within clusters were determined
to be of highest interest and were found on chromosomes 5, 10, and 11. These SNP’s are
described according to their corresponding gene function and relevance to the phenotype
of breast cancer.
Differences in Genotype
As previously described, chromosome 5 displays a significant SNP_1907286
(-log 10 p= 4.8) at position 31786818. This SNP is associated with the PDZD2 gene and
is found in an intron and falls within the outer boundaries of the transcript record [29].
The PDZD2 has a physical position of 31834787-32146794; therefore, the SNP is not
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located within the gene thus a Geneset enrichment value of (p=0.49; FDR1). Next the
known allele frequency was considered. The SNP allele A/T frequency among CEPH
(Utah residents with ancestry from northern and western Europe) found the major A
allele at a 38% occurrence, minor T allele at a 62% occurrence, and a heterozygoisty
frequency of 47% [29]. Therefore, this is a commonly occurring polymorphism among
the CEPH population studies. The SNP associated gene, PDZD2 has been noted to be
associated with prostate tumors but no association with breast cancer. The PDZD2 gene
contains PDZ domains that have been shown to bind the C-termini of transmembrane
receptors or ion channels and could be involved in intracellular signaling. The protein
encoded by this gene contains six PDZ domains and the encoded protein localizes to the
endoplasmic reticulum and is thought to be cleaved by a caspase to produce a secreted
peptide containing two PDZ domains. The gene has been found to be unregulated in
primary prostate tumors [83].
The largest cluster of differentially expressed allele frequencies was found on
chromosome 10, over a region of 6.1 kilobases with 11 differentially expressed SNP’s
between cases and controls. As previously described, two highly significant SNP’s within
this region are SNP_A-2181577 (-log 10 p=3.97) and SNP_A-2006464 (-log 10 p=3.97)
at position 127481155 and 127485797 and statistically associated with the UROS gene
(p=.001; FDR 1) located at position 127467141-127501757. Both SNP’s are found in
the gene intron and fall within the outer boundaries of the transcript record [29]. SNP_A2181577, allele C/T among the CEPH population has a major allele frequency of 61%,
minor allele frequency of 38.6% and a heterozygosity frequency of 47.4%. SNP_A2006464, allele A/C among the CEPH population has a major allele frequency of 59%,
minor allele frequency of 41% and a heterozygosity frequency of 48% [29]. The UROS
(uroporphyrinogen II synthase) gene encodes a gene which catalyzes the fourth step of
porphyrin biosynthesis in the heme biosynthetic pathway and is found to have no
correlation with the phenotype of breast cancer [83].
SNP_A-1842005 (-log 10 p= 3.98) at position 127508528 was found to be the
most significant SNP within the region of chromosome 10 and was statistically associated
with the BCCIP gene (p=.001; FDR 1) located at the physical position of 127502104127532080. SNP_A-1842005, allele C/T among the CEPH population has a major allele
frequency of 59%, minor allele frequency of 40%, and a heterozygosity frequency of
48% [29]. The BCCIP gene is a BRCA2 and CDKNIA interacting protein and was
isolated due to its interaction with BRCA2 and p21 proteins. It is an evolutionarily
conserved nuclear protein with multiple interacting domains. Functional studies indicate
that this protein may be an important cofactor for BRCA2 in tumor suppression, and a
modulator of CDK2 kinase activity via p21. Several transcript variants encoding different
isoforms have been described for this gene [83]. This gene may prove to be very
important within this cohort due to the BCCIP gene interaction with BRCA2 and
association with breast cancer phenotype.
The BCCIP gene is of interest due to its interaction with the tumor suppressor
BRCA2 and association with the phenotype of breast cancer. The function of BCCIP was
first described due to its interaction with BCRA2 and CDKN1A (p21) [96]. BRCA2 is
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known to be a tumor suppressor and is involved in DNA repair contributing to genomic
stability [97], regulation of mitosis and cytokinesis ensuring numerical chromosomal
stability [98]. Lu et al [99] described the chromatin-bound fraction of both BCCIP
isoforms colocalize with BRCA2 and contribute to BRCA2 and RAD51 nuclear focus
formation. A recently published study found that downregulation of either BCCIP
isoform significantly reduces DNA double strand break-induced homologous
recombination, impaired G1/S checkpoint activation, abrogates p53 transactivation and
down-regulates p21 expression [100, 101]. Therefore, BCCIP expression may regulate
genomic stability through multiple pathways including homologous recombination repair,
S checkpoint, and cytokinesis. Additionally, BCCIP may regulate centrosome stability
through p53 and p21 function, sequestering p53 protein from the p21 promoter despite an
elevated total p53 protein level [101]. Due to the importance in genomic stability, BCCIP
loss may lead to tumorgenesis and becomes an important candidate gene for the
phenotype of breast cancer.
Within this polymorphic region there were two other significant regions of allele
frequency differences between cases and controls, SNP_A-1944367 (-log 10 p= 3.55)
located at position 127555310 and SNP_A-1887998 (-log 10 p= 3.47) located at position
127455338. SNP_A-1944367 is located within the intron of the gene DHX32 (p=.001:
FDR 1) and falls within the boundaries of the transcript record. The allele C/T among
the CEPH population has a major allele frequency of 40%, minor allele frequency of
60%, and heterozygosity frequency of 48% [29]. The gene DHX32 (Dead box
polypeptide 32) is characterized by the conserved motif Asp-Glu-Ala-Asp (DEAD)
which are putative RNA helicases. They are implicated in a number of cellular processes
involving alteration of RNA secondary structure such as translation initiation, nuclear and
mitochondrial splicing, and ribosome assembly and may be involved in cellular growth
and division.
The DHX32 gene is of interest due to its role in RNA metabolism which was
found to be a significant pathway within the analysis of global gene expression. DHX32
gene expression has been found to be down-regulated in acute lymphoblastic leukemia,
lymphoblastic lymphoma, and follicular lymphoma. Inversely the DHX32 has been found
to be up-regulated in mantle cell lymphoma, B-cell lymphoma, and Reed Sternberg cells
in cases of nodular sclerosis Hodgkin lymphoma have been found to strongly express
DHX32 [102, 103]. Not only has the DHX32 gene expression been association with
Hodgkin lymphoma, DHX32 is an anti-sense to the BCCIP gene. The last three exons of
the BCCIP gene overlap the 3'-terminal seven exons of the DHX32 gene [102].
The second SNP of significance within this region, SNP_A-1887998 is located
downstream 11800 bases from the transcript of the gene UROS and 958 bases upstream
from the transcript of the gene MMP21 (p=.001: FDR 1). The allele C/T among the
CEPH population has a major allele frequency of 69%, minor allele frequency of 30%
and heterozygosity frequency of 42%. The MMP21 gene (matrix metallopeptidase 21)
encodes a member of the matrix metalloproteinase family involved in the breakdown of
extracellular matrix for both normal physiological processes, such as embryonic
development, reproduction, and tissue remodeling,and disease processes, such as asthma
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and metastasis [82]. The MMP21 gene has been found to contribute to tumor
development and polymorphisms within this gene have been associated with an increased
risk of cancer [104, 105].
The analysis found the most significant SNPs, SNP_A-2294376 (-log 10 p=5.1)
and SNP_A-2209464 (-log 10 p=5.2), to be located on chromosome 11 at position
119148037 and 119149661 and are associated with the genes TRIM29 and PVRL.
SNP_A-2294376 is located upstream at a distance of 43392 nucleotide bases from the
transcript of PVRL1 and downstream 339168 nucleotide bases from the transcript of
TRIM29. SNP_A-2209464 is located upstream at 45016 nucleotide bases from the
transcript of PVRL1 and downstream 337544 nucleotide bases from the transcript of
TRIM29. Due to the SNP location in relation to the gene, these genes were not
statistically associated with the SNP in the Geneset enrichment file, TRIM29 (p=0.845)
and PVRL (p=0.142).
Genotype Summary
Aim two found that there were differences in the genotype of those with and with
out breast cancer and the most significant genotype differences were found on
chromosomes 5, 10, and 11. A region within chromosome 10 was found to have the
largest cluster of significant genotype variability and genes that are of importance to the
breast cancer phenotype. From this analysis, SNP’s within the BCCIP and DHX32 gene
were found to statistically significant, overlap in physical position, and have been
described as being associated with the phenotype of breast cancer and Hodgkin
lymphoma. Additionally, polymorphisms within the gene MMP21 as described have been
associated with an increased cancer risk. The region within chromosome 10 becomes is
of importance for further validation and analysis due to the strong association with the
phenotype not only of breast cancer but of Hodgkin lymphoma.
Primary Aim Three
Copy Number Variation
Aim three identified inferred regions of 14q11.2 and 15q11.2 through copy
number variation to have some association with case/control status. It is known that copy
number variation is integral in the genomic variation between individuals. However, the
extent to which genetic variability contributes to disease is unknown. One study suggests
that copy number variations greater than 100 kilobases contribute to genetic variation and
found these large scale variations to differ by 11 copy number polymorphisms with an
average length of 465 kilobases [106]. Nozawa et al [107] found that 14.2% of the human
gene loci have copy number polymorphisms. Therefore, regions of copy number
variation are not uncommon but will vary according to those sampled. Although the
effect of copy number variation on the phenotype is unknown, it is thought that the effect
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is significant given the impact of copy number variation on gene expression [108]. Copy
number variation requires additional analysis of the genotype data. This can be explained
in that the SNP genotype assumes 2 copies and will force variants to conform to the chip.
For example, the region of copy number variation amplification may have a genotype of
AAB, which will be recorded as AA or AB on the SNP chip without inference to the
additional allele. Therefore, this study analyzed the genotype data for areas of copy
number variation. This analysis found regions of copy number variation at 14q11.2
(p=0.069) and region 15q11.2 (p=0.067). From the copy number polymorphisms the logtransformed Affymetric U133 plus expression signal by inferred copy number status for
each of two probe sets mapped to genes that overlap or are located with 5,000 base pairs
of the copy number variation region. This provided the candidate genes for the two
regions of interest.
The region of 14q11.2 was mapped to two genes OR4N4 and OR4Q3. These
genes are olfactory sensory genes and one of the largest gene families with the genome.
The sensory genes have been studied due to their large number of copy number variations
[109, 110]. It is thought that this variation is the result of physiological requirements in
response to ones environment [107]. In addition, the sensory gene families are thought to
contain a large number of pseudo genes [103, 104] that appear to have experienced
random change in copy number variation and have undergone genetic drift [111]. This
region of variation is well documented and most related to evolutionary change.
The region of chromosome 15q11-13 has been found to be one of the most
unstable regions within the genome [112]. Clinical cytogenetic analysis have frequently
identified a region of amplification on 15q that has not been associated with PraderWilli/Angleman Syndrome and appears to have no significant effect on phenotype [113,
114]. This region of amplification has also been studied for patterns of inheritance and
found inherited from either sex parent with no apparent parent of origin effect [115].
Another study followed 130 families with unbalanced chromosome abnormalities at five
regions including 15q11-13 and 70 families with euchromatic variants including 15q11.2
[116]. Among the families with an unbalanced chromosome abnormality, 9 families had a
duplication of this region with either an affected child or an affected parent and child.
Expression of phenotype was due to involvement of the critical Prader-Willi region and
included developmental delay and autism. Thirty two families were found to have
euchromatic variants within the region of 15q11.2. Euchromatic variants reflect copy
number variation of segements of genes and pseudogenes which are polymorphic in the
general population and typically have no phenotypic effect. This study found 32 families
to have duplications within 15q11.2. This gain in copy number is thought to be the result
of additional copies of the NF1 pseudogene. Additionally, the study notes that similar
variation my be expected at other sites of the NF1 pseudogene including 14q11.2 [116].
Another study has also documented the 15q duplication has being inherited from either
parent with no effect on phenotype, and related to the polymorphic regions of pseudogene
sequences [115]. Within this analysis of copy number variation, 11 controls were found
to have duplication at 15q11.2; no case was found with duplication. From the described
studies and this duplication only occurring within the controls, it is likely a common
inherited variant with no effect on phenotype.
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The occurrence of deletion was found in 4 cases and 9 controls, including the one
case who has died from breast cancer progression and a control who has died from
another secondary tumor. Deletion within this region has typically been described with
Prader-Willi and Angleman Syndrome. A search of the literature found no reports of a
deletion at this region in association with the phenotype of breast cancer or Hodgkin
lymphoma. However, the analysis of family history as described earlier did find an
association (p=0.039) with the deletion and first degree relative with breast cancer for
both the cases and controls.
The remainder of the cases and controls had no change within this region.
However, in reviewing the data it is important to keep in mind that this analysis compares
signal values from within the cohort to themselves. Therefore, it is most likely that many
of the copy number variations were missed. It is likely that many of those found in the
analysis to be no change may actually have a duplication or deletion when the validation
real-time PCR is complete. It is less likely that those with a duplication or deletion in this
analysis become no change (two copies). This conclusion is inferred from the ad hoc
statistical approach.
The location of the copy number variations produced a list of candidate genes for
the 15q11.2 region. This list included CYFIP1, PAK2, RNF145, NIPA1, NIPA2, BCL8,
TUBGCP5, and numerous hypothetical proteins. Expression of these genes was not noted
to be directional according to copy number variation. A review of the literature explored
the association of these candidate genes with the phenotype of lymphoma, cancer, and
breast cancer.
The region of 15q11-13 has been found to be a site of rearrangements in 3-4% of
those diagnosed with diffuse cell large cell lymphoma and is the location of BCL8 a Bcell lymphoma gene [117]. The BCL8 was found due to this recurrent site of
rearrangements in a small number of large cell lymphoma patients. The function of BCL8
is not understood but it is ectopically activated in lymphomas. Furthermore, it is
speculated that this site rearrangement is most likely related to mutations in the
regulatory region or deregulation by a trans-acting factor or gene deregulation by changes
in the imprinting pattern of the chromosomal region [117].
Two of the candidate genes, PAK2 and CYFIP1 are within the tyrosine kinase
family. Tyrosine kinases are enzymes that transfer a phosphate group causing
phosphorylation after a factor binds to its receptor. This allows the cell to participate in a
chemical reaction such as activation of a signaling pathway. CYFIP1 is a tyrosine kinase
which has been found to have differential expression during breast cancer development
[118]. The serine threonine protein kinase, PAK2 is activated by cellular stress such as
hyperosmolarity, ionizing radiation, and DNA damage. PAK2 executes part of the
cellular response to stress by inhibiting activity of Myc and may be a tumor suppressor
[119]. Expression of PAK2 is frequently affected by rearrangements associated with
hematological malignancies such as chronic lymphocytic leukemia and B-cell lymphoma.
The interaction between Myc and PAK2 may be bidirectional, in that Myc may down
regulate PAK2 [120]. Lastly, candidate genes, NIPA1 and TUBGP5 have recently been
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documented as having potential implication in the development of breast cancer in LiFraumeni syndrome animal model [121].
Copy Number Variation Summary
The copy number analysis found some association with case/control status and
copy number variation at 14q11.2 and 15q11.2. Amplification with this region in those
with no phenotype effect has been described as an euchromatic variant and likely related
to the polymorphic segment of the NF1 pseudogene [115, 116]. However, the deletion is
not described within the literature and may be of interest with the phenotype of breast
cancer. This is further warranted with the association noted between the deletion among
the cases and controls and family history of breast cancer. Lastly, the region of 15q11.2
provides another list of potential candidate genes that may be associated with the
development of breast cancer among HL survivors. The genes of greatest interest include
CYFIP1, PAK2, NIPA2, and TUBGCP5 which have been cited in the literature as being
associated with the phenotype of breast cancer as previously described. An analysis is
ongoing to validate the presence of amplification or deletion within the 15q11.2 region of
interest.
Relation of Study Results to Conceptual Framework
This study evaluated the similarities and differences in global gene expression,
genotype, and copy number variation among females treated for pediatric HL with and
without the development of secondary breast cancer. The conceptual model (see Figure
1.1) depicts each individual with treatment related risk factors including age at treatment,
dose of mediastinal and pelvic radiation, and dose of alkylating agents. There were no
statistical differences in age, mediastinal radiation, or alkylating agents; however, there
were differences between the cases and controls receiving pelvic radiation and age of
menopause. It is these treatment characteristics and their interaction with inherited
characteristics that place the individual at an increased risk of secondary breast cancer.
Therefore, the family history was assessed between the cases and controls, with no
differences noted. However, at the time of therapy the family history is less suggestive of
potential breast cancer risk and should be reevaluated with the passage of time.
Additionally, at the time of therapy, the individual’s genetic influences are unknown;
therefore, the individual’s ability to maintain genomic stability after the initiation of
radiation and chemotherapy at a young age is unknown. Females who maintain genomic
stability have ablation of tumor and cellular apoptosis or DNA repair secondary to the
genomic insult of radiation and chemotherapy. Females who are unable to maintain
genomic stability will retain mutated lesions and with additional insults over time will
likely develop secondary breast cancer.
This study found differences in gene expression, genotype, and a region of copy
number variation among the cases and controls. These findings will require a step wise
validation with further analysis and subsequent study. If validated these findings could be
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used as a screening for females at potential risk of secondary breast cancer after HL
therapy. While these validation studies are on going, changes in the conceptual model
should include a periodic update of the individual’s family history. Future studies will
continue to match treatment variable between cases and controls and will include pelvic
radiation. Lastly, each individual should be made aware of lifestyle characteristics that
reduce additional genetic insults such as healthy diet (folic acid, methionine, and
selenium), limited sun exposure, non smoking, use of hormonal therapy and limited
alcohol intake. For young females undergoing pediatric cancer therapy, their family
history may not be noted as positive for breast or other cancer. However, these females
should understand the importance of their family history, lifestyle characteristics and the
implications these have for their own health risk. There will be an ongoing assessment of
the conceptual framework in subsequent studies.
Nursing Implications
This study has implications for nursing research and practice. The knowledge
gained could provide a larger framework of research in the exploration of the biological
mechanism underlying early on-set breast cancer after a childhood cancer. With an
improved understanding of inherent risk factors, the biological mechanism, and the
interaction of endocrine influences, this finding could assist in developing a predictive
clinical model. It is reasonable that future treatment approaches may require screening for
breast cancer-related polymorphisms or copy number variations prior to treatment of
pediatric HL. If future screening identifies an individual with a genetic predisposition for
the development of breast cancer, therapy may be modified in an effort to decrease this
risk. This may include a modification of radiation, chemotherapy, hormonal therapy posttreatment therapy, or the administration of anti-estrogen therapy. The individual and
family would be informed of and develop an understanding of potential risk and the
measures that are needed to heighten surveillance. This surveillance should also entail an
annual review of the individual’s family cancer history and most specifically that of
breast cancer among primary and secondary degree relatives. In practice the oncology
nurse would navigate the individual through a surveillance plan which would include
monthly self-breast exam, counseling in obtaining a biannual physician breast exam and
annual diagnostic imaging. The nurse should provide counseling that may reduce
oxidative stress and genomic insults through lifestyle characteristics such as healthy diet
(folic acid, methionine, and selenium), limited sun exposure, non smoking, limited use of
hormonal therapy and limited alcohol intake. Lastly, the nurse can explain and
disseminate these findings to primary care providers caring for these women.
Limitations
The major limitation of this study is the small sample size of 13 cases and 36
controls. While SJCRH is a large center for patient accrual with secondary breast cancer
after pediatric HL, only 14 known secondary breast cancer survivors where eligible at the
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time of patient enrollment. To compensate for the small case sample size, matching of
three controls did improve the efficiency for binary measures.
Another limitation of the study is the generalizability of the study findings. This
study was designed to explore the mechanism of secondary breast cancer after pediatric
HL; therefore, this study can not be generalized to sporadic breast cancer and will need
further study among those with breast cancer after other pediatric cancers. Cases and
controls were screened for active disease prior to blood collection; however, both cases
and controls have subsequently reported disease reoccurrence or newly diagnosed
disease. Therefore, the gene expression data may be affected by current disease status.
Lastly, genomic analysis is moving at a rapid pace and provides numerous biostatistical
and bioinformatical methodological limitations.
Recommendations
Recommendations for Research
These data and analysis provide a vast number of future hypotheses generating
questions.
1. The study findings must be validated by real time PCR to determine the
presence of candidate polymorphisms and a gain, loss or no change at15q11.2
2. Further analysis of data to determine if variation in gene expression is related
to genotype or copy number variation.
3. The study should be replicated in females treated for other pediatric cancers
who develop secondary breast cancer and all new cases of HL associated
breast cancer.
4. The current data should be compared to other genomic data sets that have
evaluated germline polymorphisms among survivors of other pediatric cancers
and females with sporadic breast cancer.
5. Further studies should utilize the DNA repository that was imitated through
this study and access other polymorphisms of interest that were not included
in the 500K genotyping such as the polymorphism associated with MDM2.
6. Additional analysis of the cases and controls in comparison to other genomic
data sets to explore genomic etiology that may be associated with pediatric
HL.
7. If the findings are replicated in associated studies, prospective screening may
be appropriate in the diagnostic HL evaluation.
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Recommendations for Practice
Currently, these study findings will not have application in clinical practice.
However, if the real time PCR finds the locus of interest to be valid, findings may have
clinical implications. The study should first be replicated within a larger HL cases/control
designed study. If the findings are consistent and the loss (deletion) is found to be
associated with secondary breast cancer, controls that have the deletion will require
heightened monitoring and breast cancer surveillance. If the locus of interest is validated,
evaluation may become routine for the newly diagnosed HL patient prior to the initiation
of therapy.
Conclusion
This study was an unbiased genome scan of germline DNA and RNA with unique
and common loci identified and provides a data base for additional analysis. This study
explored the global gene expression and genotype between females treated for pediatric
HL with and without the development of secondary breast cancer. To the best of my
knowledge, this is the first genome wide association study among female HL survivors
with and without secondary breast cancer. With the use of two genome wide approaches,
this study found differences in global gene expression, genotype, and two regions of
copy number variation that were associated with case/control status. The study did find
that the global gene expression is different among cases and controls with differences in
amino acid metabolism, translation, and DNA repair giving a list of candidate genes with
these pathways. Secondly, the study found that there were differences between cases and
controls and their genotype expression. Of particular interest are genotype differences
with the BCCIP and DHX32 genes which have association with the phenotype of breast
cancer and Hodgkin lymphoma. Lastly, the genotype data were screened for
amplifications and deletions and found a near significant region of variability. The
deletion of the region was found to be associated with a first degree family history of
breast cancer; therefore, these women warrant continued follow-up for the development
of breast cancer. Lastly a set of genes were described within this region and documented
within the literature as being associated with the phenotype of breast cancer. This data
analysis warrants validation of findings and further data analysis in determining potential
candidate genes and genotypes in association with the development of breast cancer after
pediatric Hodgkin lymphoma.
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APPENDIX B. INTRODUCTORY LETTER
Date
Patient’s Address
Dear (Patient’s Name),
We are writing to you and other women who were treated at St. Jude Children’s Research
Hospital for pediatric Hodgkin disease to ask your participation in a new research study.
We will describe the study in this letter, and we welcome any questions you may have.
Women who were treated for pediatric Hodgkin disease are at an increased risk for
development of breast cancer with the greatest risk occurring 15 to 20 years after
Hodgkin disease. Researchers do not yet understand all the factors associated with
increasing a women’s risk of breast cancer after Hodgkin disease therapy. We would like
to learn why some female Hodgkin disease survivors develop breast cancer while other
female Hodgkin disease survivors do not. We believe that a better understanding may be
obtained by exploring the genetic differences that affect a woman’s tolerance to radiation
and chemotherapy. Therefore, we have chosen to conduct a research study that will
examine and compare the genetic differences between pediatric Hodgkin disease
survivors who developed breast cancer to those pediatric Hodgkin disease survivors who
have not developed breast cancer.
We will contact you by phone within two weeks after you receive this letter. During that
call, we will ask if you would like to participate in this study. If you agree to participate,
we will ask you to give verbal consent and complete a10 item questionnaire over the
telephone. The verbal consent and questionnaire conversation will be taped; the tape will
not begin until you give taping approval. The tape will be in a locked cabinet and can not
be linked with you. The tape will be destroyed after the completion of the study and
publication of study findings. We have enclosed the questionnaire for your review.
We will also ask that you read, sign, and return the enclosed consent form. The consent is
enclosed along with an explanation of this study. Once we have received your signed
consent, we will ask that a blood sample be obtained at your local physician’s office, a St.
Jude affiliate clinic, or at St. Jude Children’s Research Hospital. We will pay for the cost
of the blood sample.
Please know that you do not need to take part in this study-it is voluntary. Please feel free
to contact either of us at the hospital with any questions about this study (901) 495-4209.
We would be glad to have the opportunity to discuss it with you. Our very best to you
always.
Belinda Mandrell, PhD candidate, RN
Melissa Hudson, MD
RESEARCH PARTICIPANT STATEMENT
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APPENDIX C. INFORMED CONSENT STATEMENT
THE MOLECULAR PROFILE OF WOMEN WITH AND WITHOUT
SECONDARY BREAST CANCER AFTER TREATMENT OF PEDIATRIC
HODGKIN DISEASE
You are being asked to take part in a research study because you were treated for
pediatric Hodgkin disease. This study will help researchers understand more about why
some women treated for Hodgkin disease develop treatment-related breast cancer while
other women do not. This study is not testing for a genetic or inherited disease (passed on
in families) but is looking at genetic differences that may help explain how the body
responds to radiation and chemotherapy. This research approach may help identify risk
factors for secondary breast cancer at the time of Hodgkin disease diagnosis. If so, that
information could be used to adjust Hodgkin therapy.
This consent form gives you information about the study, which will be discussed with you. Once you
understand the study, and if you agree to take part, you will be asked to sign this consent form. You will be
given a copy of the consent form to keep.
Before you learn about the study, it is important that you know the following:

•
•
•

Whether or not you take part in this study is entirely up to you.
You may decide not to be in the study, or to withdraw from the study at any time.
This study is being sponsored by the American Cancer Society, National Institutes of
Health, and St. Jude Children’s Research Hospital. The sponsors will receive
anonymous information about your treatment characteristics as related to the study.

Why is this study being done?
We now know that after treatment for pediatric Hodgkin disease, patients can have
problems with late effects from Hodgkin therapy. For women treated for pediatric
Hodgkin disease, the risk of developing breast cancer is higher than among the general
population. Doctors caring for Hodgkin disease survivors are not sure why some women
develop breast cancer and others do not. The purpose of this research study is to compare
genes in women treated for pediatric Hodgkin disease who develop breast cancer to the
genes of women treated for pediatric Hodgkin disease who did not develop breast cance
The study has the following primary goals:
1. To assess for a difference in the RNA (gene appearance) of women who received chest
radiation for pediatric Hodgkin disease and later developed breast cancer or did not.
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2. To assess for a difference in the DNA of women who received chest radiation for
pediatric Hodgkin disease who later developed breast cancer with the DNA of those
women who did not develop breast cancer.
3. To assess if genes may be identified through the study of RNA and DNA that may
represent a women’s higher risk of developing breast cancer after Hodgkin disease
therapy.
The study has the following secondary goal:
1. To assess for any association between the use of hormones, childbirth, and family
history and the development of secondary breast cancer.
How many research participants will take part in the study?
Forty eight (48) women treated at St. Jude Children’s Research Hospital, from 19701991, for pediatric Hodgkin disease who subsequently did or did not develop breast
cancer will be asked to participate in the research study.
What is involved in this study?
As a survivor of pediatric Hodgkin disease you are invited to participate in this study.
This research study has two parts:
1). A telephone interview asking questions about
a) your use of hormones for birth control, fertility or ovarian failure
b) pregnancies
c) family cancer history
2). Collection of a blood sample.
You will be ask to join this study only after you have been fully informed by way of the
enclosed letter and telephone conversation with the primary researcher, your questions
have been answered, and you have verbalized an understanding of the study. After
obtaining your verbal consent during the phone conversation, you will be asked to
respond to 10 questions regarding your use of hormones for birth control, ovarian failure,
or fertility. You will also be asked your history/date of pregnancies and your family
history of cancer. You will also need to give your written consent using the attached
consent forms. These forms will need to be returned to St. Jude in the enclosed envelope.
You will also be instructed on blood collection. The blood collection will require 11 mls
(2 teaspoons) of blood. This blood may be collected at St. Jude, an affiliate clinic, or at
your local doctor’s office. All supplies and instructions will be forwarded to your doctor
and the blood will be returned to St. Jude by express mail. Participants will only be
enrolled once in this study. All samples will be mailed via Federal Express to the
RNA/DNA extraction lab of Dr. Mary Relling, St. Jude Children’s Research Hospital,
332 North Lauderdale, Memphis, TN 38105. You will not pay for any of these costs. All
costs will be paid from a grant at St. Jude. The consent process will be documented in the

106

medical record as per institutional guidelines. We also ask you to allow us to save any
left over DNA not used in this study. We seek your permission to store the left over DNA
for potential future research questions regarding pediatric Hodgkin disease and breast
cancer. This DNA will not be stored with your name and will only be identified by an
assigned number. Your DNA will be used only for research and will not be sold.
How long will I be in the study?
Once you have submitted the blood, you will be considered off study. You will receive a
follow-up letter after the study is completed with an abstract of the study, in which
findings from the study will be described. If you have further questions after reading
these findings, you may call the primary research investigator, Belinda Mandrell at (901)
495-4209.
What research studies will be done?
DNA and RNA will be extracted from your blood. The DNA will be analyzed looking for
common differences between participants with a technique called Single Nucleotide
Polymorphisms (SNPs). The RNA will be analyzed looking at differences in gene
expression using a technique, microarray analysis. This is not a diagnostic technique and
is a research analysis only.
What will I learn about the results of this study?
Your individual test results are not linked to your personal information, and are
unavailable to the investigators, we are unable to report them back to you.
What are the risks of the study?
The researchers in this study will protect your records and blood sample and insure that
your samples will be labeled without your name and will not be directly linked to you.
The results of this research will not be added to your St. Jude record.
The risk from blood collection will be related to having a needle put into a vein which
may cause a feeling of faintness, pain, bruising, and a minimal chance of infection.
What are the benefits of this study?
This research approach may help identify risk factors for breast cancer at the time of
Hodgkin disease diagnosis and could result in adjustment of Hodgkin therapy. The future
benefit of participation in this study is for others who will be learning more about what
causes cancer, how to prevent second cancers, and how to offer better treatment. This
research may help children with Hodgkin disease in the future.
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What are the consequences of not joining the study?
You can choose to not join or to stop participating in the study at any time. Your
participation is voluntary. The alternative to participating in this study is not to
participate. You may contact us anytime at (901) 495-4209 and tell us you do not want
your information or blood used for this study. Your information and your blood specimen
will be discarded and no longer used for research.
Compensation
There is no cost to participate in this study. There is no payment for participation.
Confidentiality
Your medical records will be kept confidential to the degree allowed by law. Information
from your medical records will not be given to anyone outside the hospital unless you
agree. You will not be identified in any publication about this study.
Government agencies oversee research studies involving people. Your medical records
may be reviewed by such agencies if you take part in this research study. These agencies
may include the Food and Drug Administration (FDA) and the National Cancer Institute
(NCI). Anonymous information regarding your treatment characteristics and the study
results may also be shared with researchers from other institutions that are involved in
this study. These include the American Cancer Society and the National Institutes of
Health. By signing this consent form, you are allowing your medical records to be
reviewed by these persons.
It may be necessary to check parts of your medical record to be sure that your original
treatment for Hodgkin disease is recorded correctly and completely. Such a check might
be done by the following groups:
1. A federal agency such as the Food and Drug Administration (FDA) or the National
Cancer Institute (NCI).
2. St. Jude Children’s Research Hospital Institutional Review Board, a committee that
reviews the ethics of research studies.
3. American Cancer Society
No information other than what is needed for the study is recorded. Every effort is made
to protect your privacy.
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APPENDIX D. SUMMARY OF RESEARCH AND PRIVACY RIGHTS
Non-Therapeutic Research
IRB version: November 4, 2003

I have been told the following information:

1. I may talk as much as I want to with the doctors who are responsible for my care
about the reasons for this study and about its risks.
2. This study may have risks that the researchers do not know about now.
3. There will be no additional costs to me from taking part in this research study. It is
the policy of St. Jude Children’s Research Hospital not to bill research participants or
their families for the cost of medical care. This includes any costs associated with
taking part in research studies.
4. I and my family will not receive any compensation or payment of any kind for being
in this study, or for any treatments, products, or any other things of value that may
result from this study.
5. The hospital policy is not to provide payment if I am injured or damaged by being in
this study
6. I have been told that I can withdraw from this study at any time.
7. I received a copy of the St. Jude Notice of Privacy Practices at the time of
registration. That document tells me how my medical information may be used or
disclosed (given to someone outside the hospital). I have been told I have the right to
review the Notice of Privacy Practices before I sign this form. I have been told that I
may request another copy of the Notice of Privacy Practices and that it is posted in
the Hospital and on our website (www.stjude.org).
8. I have the right to inspect, copy and/or amend (change) my protected health
information that is to be used or disclosed. I have been told in this consent form
about any limitations to this right, such as research information that I will not have
access to until the end of the study or that will be used strictly for research purposes.
9. My protected health information will be disclosed to or used by the following:
• Investigators and co-investigators of research study
• American Cancer Society
• National Institutes of Health
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10. My records may also be reviewed by agencies such as the Food and Drug
Administration or the National Institutes of Health, or other agencies as required by
state or federal regulations.
11. Information about me that may be disclosed includes the following:
•

Complete medical record including information regarding diagnosis, illness,
treatment, and information that may be recorded about previous diagnosis or
treatment.

•

Information gathered as a part of this research study as explained in the informed
consent/authorization.

12. I have been told that once my records are disclosed to or used by others, St. Jude
Children's Research Hospital cannot guarantee that information will not be further
disclosed. Also, the released information may no longer be protected by federal
privacy regulations.
13. I have been told that this authorization for the use and disclosure of my protected
health information does not expire.
14. I have been told that I may withdraw my authorization for the disclosure or use of my
records at anytime, for any reason, with the following exceptions:
•
•

When that information has already been disclosed or used based on my
permission
When the information is required to maintain the integrity of the study

15. To withdraw my authorization, I must complete a Revocation of Release of
Authorization form. I have been told I may request this form at St. Jude Children's
Research Hospital by calling the Privacy Officer at 901-495-2341. The form must be
returned by mail or hand delivery to:
HIPAA Privacy Officer
St. Jude Children's Research Hospital
332 N. Lauderdale
Memphis, TN 38105
16. I know that if I have more questions about this study or about any injury from the
treatment, I can call the Principal Investigator of this study, Belinda Mandrell at
901/495-3300.
17. I know that I can get more information about my rights as a research participant by
calling the Chairman of the Institutional Review Board at 901/495-4357 or the
Research Participant Advocate (Ombudsman) at 495-4644. If I am outside of the
Memphis area, I may call 1-866-583-3472 (1-866-JUDE IRB). This is a toll-free call.
18. I will receive a copy of this signed statement.
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19. I have asked to allow the principal investigator to store any left over DNA for
potential future research questions regarding pediatric Hodgkin disease and/or breast
cancer. The DNA will not be stored with my name and will be identified by an
assigned number
_/_______ I agree to have my DNA stored for potential future research
_/_______ I do not agree to have my DNA stored for potential future research

PLEASE FAX WITH CONSENT SIGNATURE PAGE TO PROTOCOL OFFICE #6265
I have read (or have had read to me) the contents of this document and have been
encouraged to ask questions. I have received answers to my questions. I give consent to
take part in this research study and authorize the disclosure and use of my protected
health information for the purposes of that research.

______________________________
Research Participant
Date

________________ _______________
Time (AM/PM)

PHYSICIAN/INVESTIGATOR/DESIGNEE STATEMENT
I hereby certify that I have discussed the research project with the research participant. I
have explained all the information contained in the informed consent document,
including any risks that may be reasonably expected to occur. I further certify that the
research participant was encouraged to ask questions and that all questions were
answered.
______________________________
Physician/Investigator/Designee

________________
Date

_______________
Time (AM/PM)

In case of questions or emergencies in reference to this protocol, please contact:
St. Jude Children's Research Hospital
332 North Lauderdale
Memphis, TN 38105
(901) 495-3300 - FAX Interdepartmental #6265
PLEASE FAX CONSENT FORM TO PROTOCOL OFFICE #6265
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APPENDIX E. DEMOGRAPHIC QUESTIONNAIRE OF HODGKIN DISEASE
SURVIVORS
1. Do you have menstrual periods? Yes

No

2. What was your age at your first period? ___________________________________
3. What was your age at your last period or menopause?________________________
4. Have you used hormone (estrogen/progesterone) medication for birth control, to stop
bleeding, to regulate your periods, or help with symptoms of menopause? Yes No
If yes, give date or age of starting hormone use and reason of use ________________
____________________________________________________________________
Are you currently on hormone medication? Yes
No
If yes, give name of current hormone medication_____________________________
If no, Please give the general date for starting and stopping hormone medication
Started___________________________
Stopped__________________________
5. Have you ever been pregnant?
Number of pregnancies __________, Number of live births________
Date(s)of Birth

Did You Breast Feed, if yes how long

1.
2.
3.
4.

6. Please describe your family history of cancer, give blood relative (grandmother,
grandfather, mother, father, aunt, uncle, sister, brother, children). Also note if the relative
is from your mother’s (maternal) or father’s (paternal) side of the family.
Relative
1.
2.
3.
4.
5.
6.
7.

Type of Cancer

Age at Cancer Diagnosis
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Living or Deceased

7. Have you had a breast exam by a doctor within the last year?
8. Have you had a mammogram within the last year? Yes

Yes

No

No

9. Have you been diagnosed with any other cancers since treatment of pediatric Hodgkin
Disease? Yes
No
If yes, list cancer _________________________
10. Please answer if you have been diagnosed with breast cancer after Hodgkin Disease
treatment.
a. What was the breast cancer histology?
Adenocarcinoma
Infiltrating Ductal Carcinoma
Ductal In-Situ Carcinoma
Other Not sure
b. Location of breast cancer: Right Breast

Left Breast

Both Breasts

c. Was the breast cancer positive for any or all of the following?
Estrogen
Progesterone
HER-2 Dont’ know
d. What was your treatment for breast cancer (check all that apply to you)
Surgery
Chemotherapy Radiation Hormone Therapy Other
e. Last date of breast cancer treatment____________________________
f. Are you currently on hormone therapy for breast cancer prevention or treatment?
Yes No
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APPENDIX F. SINGLE NUCLEOTIDE POLYMORPHIMS OF INTEREST

probeid

test.stat

test.p

perm.p

q

Probe.Set.ID

Gene
Symbol

Chromosomal.
Location

219812_at

3.985615

6.73E-05

1.00E-04

0.6786

219812_at

MGC2463

chr7q22.1

1559777_at

-3.69122

0.000223

1.00E-04

0.6786

1559777_at

---

---

207873_x_
at

-3.55535

0.000377

1.00E-04

0.6786

207873_x_at

SEZ6L

chr22q12.1

237143_at

3.55535

0.000377

1.00E-04

0.6786

237143_at

---

---

1555243_x
_at

3.419477

0.000627

1.00E-04

0.6786

1555243_x_at

C8orf59

chr8q21.2

220418_at

3.408154

0.000654

1.00E-04

0.6786

220418_at

IFT52 ///
UBASH3A

chr21q22.3

219134_at

-3.39683

0.000682

1.00E-04

0.6786

219134_at

ELTD1

chr1p33-p32

3.374186

0.00074

2.00E-04

0.6786

1560661_x_at

KIAA1641

chr2q11.2

-3.35154

0.000804

2.00E-04

0.6786

201661_s_at

ACSL3

chr2q34-q35

230319_at

-3.26096

0.00111

2.00E-04

0.6786

230319_at

---

---

242368_at

-3.66858

0.000244

3.00E-04

0.6786

242368_at

GTF2I

chr7q11.23

236503_at

3.464768

0.000531

3.00E-04

0.6786

236503_at

LOC38852
6

chr19q12

-3.44212

0.000577

3.00E-04

0.6786

219868_s_at

ANKFY1

chr17p13.3

-3.2836

0.001025

3.00E-04

0.6786

211328_x_at

HFE

chr6p21.3

45572_s_at

3.283603

0.001025

3.00E-04

0.6786

45572_s_at

GGA1

chr22q13.31

212480_at

3.600641

0.000317

4.00E-04

0.6786

212480_at

KIAA0376

chr22q11.23

1566094_at

-3.48741

0.000488

4.00E-04

0.6786

1566094_at

ARHGEF1
2

chr11q23.3

203424_s_
at

-3.32889

0.000872

4.00E-04

0.6786

203424_s_at

IGFBP5

chr2q33-q36

207264_at

-3.60064

0.000317

0.0004

0.6786

207264_at

KDELR3

chr22q13.1

221790_s_
at

3.464768

0.000531

0.0004

0.6786

221790_s_at

LDLRAP1

chr1p36-p35

236341_at

3.453445

0.000553

0.0004

0.6786

236341_at

CTLA4

chr2q33

211219_s_
at

-3.35154

0.000804

0.0004

0.6786

211219_s_at

LHX2

chr9q33-q34.1

221973_at

3.623287

0.000291

0.0005

0.6786

221973_at

LOC15075
9

chr2q11.2

219751_at

3.453445

0.000553

0.0005

0.6786

219751_at

SETD6

chr16q21

1560661_x
_at
201661_s_
at

219868_s_
at
211328_x_
at
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probeid

test.stat

test.p

perm.p

q

Probe.Set.ID

Gene
Symbol

Chromosomal.
Location

225391_at

3.419477

0.000627

0.0005

0.6786

225391_at

LOC93622

chr4p16.1

230974_at

3.419477

0.000627

0.0005

0.6786

230974_at

DDX19B

chr16q22.1

242208_at

3.374186

0.00074

0.0005

0.6786

242208_at

ZNF37B

chr10q11.21

210383_at

-3.34022

0.000837

0.0005

0.6786

210383_at

SCN1A

chr2q24.3

236436_at

3.340217

0.000837

0.0005

0.6786

236436_at

LOC28313
0

chr11q13.1

204890_s_
at

3.328894

0.000872

0.0005

0.6786

204890_s_at

LCK

chr1p34.3

229495_at

-3.19302

0.001408

0.0005

0.6786

229495_at

ACY1L2

chr6q15

243479_at

-3.4308

0.000602

6.00E-04

0.6786

243479_at

MYST4

chr10q22.2

204204_at

-3.35154

0.000804

0.0006

0.6786

204204_at

SLC31A2

chr9q31-q32

233539_at

3.328894

0.000872

0.0006

0.6786

233539_at

NAPEPLD

chr7q22.1

200013_at

3.215667

0.001301

0.0006

0.6786

200013_at

RPL24

chr3q12

238099_at

3.193021

0.001408

0.0006

0.6786

238099_at

---

---

205353_s_
at

3.170376

0.001522

0.0006

0.6786

205353_s_at

PEBP1

chr12q24.23

227412_at

3.306249

0.000946

0.0007

0.6786

227412_at

PPP1R3E

chr14q11.2

3.181698

0.001464

0.0007

0.6786

224162_s_at

FBXO31

chr16q24.2

3.170376

0.001522

0.0007

0.6786

227784_s_at

COG1

chr17q25.1

225696_at

3.102439

0.001919

0.0007

0.6786

225696_at

COPS7B

chr2q37.1

225562_at

3.487413

0.000488

0.0008

0.6786

225562_at

RASA3

chr13q34

212186_at

3.419477

0.000627

0.0008

0.6786

212186_at

ACACA

chr17q21

1561443_at

-3.37419

0.00074

0.0008

0.6786

1561443_at

---

---

217807_s_
at

3.14773

0.001645

0.0008

0.6786

217807_s_at

GLTSCR2

chr19q13.3

233771_at

3.14773

0.001645

0.0008

0.6786

233771_at

TRIO

chr5p15.1-p14

216100_s_
at

-3.26096

0.00111

9.00E-04

0.6786

216100_s_at

TOR1AIP1

chr1q24.2

227177_at

3.260958

0.00111

9.00E-04

0.6786

227177_at

CORO2A

chr9q22.3

239018_at

3.260958

0.00111

9.00E-04

0.6786

239018_at

WBSCR18

chr7q11.23

208714_at

3.14773

0.001645

9.00E-04

0.6786

208714_at

NDUFV1

chr11q13

224162_s_
at
227784_s_
at
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probeid

test.stat

test.p

perm.p

q

Probe.Set.ID

Gene
Symbol

Chromosoma
l.
Location

235697_at

3.14773

0.001645

9.00E-04

0.6786

235697_at

ZNF544

chr19q13.43

1555079_at

-3.12508

0.001778

9.00E-04

0.6786

1555079_at

C9orf68

chr9p24.2p24.1

1557258_a
_at

-3.19302

0.001408

0.0009

0.6786

1557258_a_at

BCL10

chr1p22

216166_at

3.079794

0.002071

0.0009

0.6786

216166_at

RHOH

chr4p13

234339_s_
at
221780_s_
at
1552712_a
_at

3.35154

0.000804

0.001

0.6786

234339_s_at

GLTSCR2

chr19q13.3

3.260958

0.00111

0.001

0.6786

221780_s_at

DDX27

chr20q13.13

-3.21567

0.001301

0.001

0.6786

1552712_a_at

NMNAT2

chr1q25

227915_at

3.215667

0.001301

0.001

0.6786

227915_at

ASB2

chr14q31-q32

221318_at

-3.1817

0.001464

0.001

0.6786

221318_at

NEUROD4

chr12q13.2

1558987_at

3.170376

0.001522

0.001

0.6786

1558987_at

FLJ40473

chr3q21.3

221966_at

-3.14773

0.001645

0.001

0.6786

221966_at

GPR137

chr11cenq22.3

229813_x_
at

3.14773

0.001645

0.001

0.6786

229813_x_at

DAZAP1

chr19p13.3

234116_at

-3.14773

0.001645

0.001

0.6786

234116_at

CX40.1

chr10p11.21

1563539_at

-3.12508

0.001778

0.001

0.6786

1563539_at

---

---

235784_at

3.125085

0.001778

0.001

0.6786

235784_at

MTERF

chr7q21-q22

203245_s_
at
230248_x_
at
208875_s_
at

3.260958

0.00111

0.0011

0.6786

203245_s_at

FLJ35348

chr9q34

3.260958

0.00111

0.0011

0.6786

230248_x_at

---

---

-3.07979

0.002071

0.0011

0.6786

208875_s_at

PAK2

chr3q29

1561442_at

-3.2836

0.001025

0.0012

0.6786

1561442_at

LOC28358
5

chr14q31.3

211921_x_
at

3.260958

0.00111

0.0012

0.6786

211921_x_at

PTMA

chr2q35-q36

1563101_at

-3.20434

0.001354

0.0012

0.6786

1563101_at

ARNTL2

chr12p12.2p11.2

226433_at

3.204344

0.001354

0.0012

0.6786

226433_at

RNF157

chr17q25.1

222198_at

-3.11376

0.001847

0.0012

0.6786

222198_at

---

---

243854_at

-3.07979

0.002071

0.0012

0.6786

243854_at

APLP2

chr11q23q25|11q24

-3.05715

0.002235

0.0012

0.6786

213157_s_at

KIAA0523

chr17p13.2

-3.01186

0.002597

0.0012

0.6786

205079_s_at

MPDZ

chr9p24-p22

213157_s_
at
205079_s_
at
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test.stat

test.p

perm.p

q

Probe.Set.ID

Gene
Symbol

Chromosoma
l.
Location

3.306249

0.000946

0.0013

0.6786

221208_s_at

C11orf61

chr11q24.2

-3.26096

0.00111

0.0013

0.6786

1558769_s_at

DNAH1

chr3p21.1

1560741_at

3.170376

0.001522

0.0013

0.6786

1560741_at

SNRPN

chr15q11.2

1561604_at

3.14773

0.001645

0.0013

0.6786

1561604_at

---

---

chr7q34

probeid
221208_s_
at
1558769_s
_at

211796_s_
at

3.14773

0.001645

0.0013

0.6786

211796_s_at

TRBV21-1
/// TRBV19
/// TRBV54 ///
TRBV3-1
/// TRBC1

238528_at

-3.12508

0.001778

0.0013

0.6786

238528_at

UBR1

chr15q13

243014_at

-3.09112

0.001994

0.0014

0.6786

243014_at

ZNRF3

chr22q12.1

210757_x_
at

-3.07979

0.002071

0.0014

0.6786

210757_x_at

DAB2

chr5p13

219947_at

-3.01186

0.002597

0.0014

0.6786

219947_at

CLEC4A

chr12p13
chr22q11|22q11.
23 ///
chr22q11.21 ///
chr22q11.23

226602_s_
at

3.011857

0.002597

0.0014

0.6786

226602_s_at

BCR ///
FLJ42953 ///
LOC644165
///
LOC653617

240942_at

-2.98921

0.002797

0.0014

0.6786

240942_at

HSMPP8

chr13q12.11

203848_at

3.193021

0.001408

0.0015

0.6786

203848_at

AKAP8

chr19p13.1q12

215068_s_
at

3.170376

0.001522

0.0015

0.6786

215068_s_at

FBXL18

chr7p22.2

224669_at

3.170376

0.001522

0.0015

0.6786

224669_at

DBNDD2

chr20q13.12

1566279_at

-3.15905

0.001583

0.0015

0.6786

1566279_at

---

---

233129_at

-3.14773

0.001645

0.0015

0.6786

233129_at

RYR3

chr15q14-q15

207068_at

3.125085

0.001778

0.0015

0.6786

207068_at

ZFP37

chr9q32

225067_at

3.125085

0.001778

0.0015

0.6786

225067_at

ULK3

chr15q24.1

235322_at

3.102439

0.001919

0.0015

0.6786

235322_at

LOC64973
4

---

222668_at

3.057148

0.002235

0.0015

0.6786

222668_at

KCTD15

chr19q13.11

-3.05715

0.002235

0.0015

0.6786

234106_s_at

FLYWCH1

chr16p13.3

3.034502

0.002409

0.0015

0.6786

205255_x_at

TCF7

chr5q31.1

3.011857

0.002597

0.0015

0.6786

209790_s_at

CASP6

chr4q25

234106_s_
at
205255_x_
at
209790_s_
at
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